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1.1. Pulmonary Mycobacterial Infections and Immuno-
Compromised Hosts 
Pulmonary infections, due to a variety of pathogens, are important causes of morbidity and 
mortality today especially in immuno-compromised individuals.  
The main consequence of HIV infection is a progressive depletion and disfunction of T cells, 
with defects in macrophage and monocyte functions that have a central role in anti-
mycobacterial defences. Susceptibility to opportunistic pathogens has also been found in 
patients with congenital T cell defects and in people treated with chemotherapeutic agents or 
irradiation that cause T cell depletion. Most prominent among these infections is pneumonia 
due to Pneumocystis Carinii but there has also been a high incidence of mycobacterial 
infections (1,2). 
Mycobacterial infection has been documented as a common opportunistic disease in patients 
with acquired immunodeficiency syndrome (AIDS). At Memorial Sloan-Kettering Cancer 
Center more than 400 patients with AIDS have been followed. There have been 90 
documented cases of disseminated Mycobacterium Avium Complex (MAC) infection, 11 
cases of disease due to Mycobacterium Tuberculosis (MTB), and one case of combined 
MAC-MTB infections (3).  
Tuberculosis (TB) has become a significant opportunistic disease among populations with a 
high incidence of AIDS. TB is most often due to Mycobacterium tuberculosis (MTB), and the 
lungs are the primary site of infection for the systemic pathogen but MTB can also affect  
central nervous system (meningitis), lymphatic system, circulatory system (Miliary 
tuberculosis), genitourinary system, bones and joints, (4). Among the various forms of 
tuberculosis, pulmonary tuberculosis is most commonly characterized by the involvement of 
alveolar macrophages harboring a large number of tubercle bacilli. The bacilli secrete 
molecules that prevent phagosome–lysosome fusion. Moreover, due to their very hydrophobic 
waxy cell wall, bacilli are resistant to digestion by lysosomal enzymes and hence resist the 
killing effects of macrophages. Inside the macrophages the bacteria will be either destroyed or 
begin replicating, or remain latent indefinitely. If replication is not prevented, the bacilli 
multiply and may eventually cause the macrophage to break. Problems created by bacterial 
infection are linked to their ability to survive and multiply inside the body, especially in the 
lungs, and to the natural immune response of the infected host.  
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Even today, more than one hundred year after its first description, TB is still a great health 
problem worldwide. It is estimated that there are 1 billion persons infected with tuberculosis 
worldwide, with 8 million new cases and 3 million deaths per year (5). Such high mortality 
rate seems to be due to progressive HIV infection rather than TB, and the degree of 
immunosuppression being the most important predictor of survival of HIV-TB patients. MTB 
probably increases HIV replication by inducing macrophages to produce transactivating 
cytokines (TNFα, IL-1, IL-6). 
However, immunocompromised patients are also at risk of mycobacteria other than 
tuberculosis (MOTT) infections. Recent reports have described several groups of patients 
with acute leukemia, lymphoma, visceral malignancies and treated with immunosuppressive 
therapy who have been infected with MOTT such as M. avium, M. fortuitum, M. chelonae, 
M. scrofulaceum and M. hemophilum (6, 7). Mycobacterium Avium Complex (MAC) can 
cause pulmonary disease, subacute lymphadenitis and disseminated diseases (8). MAC was 
also recognised in the AIDS pandemic as a cause of serious disseminated infection  and was 
the most common cause of systemic bacterial infection in AIDS, affecting more than 50% of 
patients in the developed countries (9). In AIDS patients with disseminated infection, the 
mononuclear phagocyte system is the predominant site of infection, but other organ systems 
such as skin, bone and joints, eyes, thyroid, adrenals, testis and the central nervous system can 
be infected (10, 11). Bacteremia occurs in most of these patients, the organism being 
predominantly in circulating monocytes. Monocytes and fixed tissue macrophages are full of 
MAC in AIDS patients, indication of the immune deficiency in these individuals (11, 12, 13, 
14, 15). Furthermore, epidemiological studies suggest that MAC strains associated with 
pulmonary disease may differ from those associated with disseminated disease in AIDS 
patients. Although if the prevalence of disseminated MAC associated disease was high, great 
individual susceptibility, and geographic and seasonal variations has been described. For 
instance, disseminated MAC is rare in Africa, although MAC is prevalent in soil and water 
samples from the area where advanced AIDS patients are present (16). This phenomena 
remains unexplained, although it is postulated that widespread previous antimycobacterial 
immunity from the high rate exposure of Africans to MTB and BCG vaccination may be 
responsible. This is supported by data that suggest that prior TB diagnosis may be somehow 
protective against disseminated MAC (17). Pathogenesis of MAC infection is incompletely 
understood. Disseminated MAC is usually believed to follow primary acquisition of the 
mycobacteria. It appears that MAC first colonizes the gastrointestinal (GI) tract or respiratory 
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mucosa, and then dissemination follows. In contrast to the immuno-compromised host, in 
which MAC disease is usually limited to the lungs, in patients with AIDS, bacteremia is by 
far the most common syndrome. Before the 1980s, infections with these bacteria were 
uncommon in humans and were recognized as a slowly progressing pneumonitis in elderly 
patients with chronic pulmonary disorders, particularly in patients with silicosis (18) and, 
occasionally, immunocompromised leukemic patients (19). Since 1981, however, numerous 
medical institutions began to report cases of MAC bacteremia in AIDS patients (20) which 
were responsible for significant morbidity and mortality in human immunodeficiency virus 
(HIV)-positive patients (21). Disseminated infections with MAC organisms are diagnosed in 
only 3% of HIV-positive patients at the time of AIDS diagnosis (22). However, these 
infections are found in about half of the autopsied patients with AIDS (23). MAC isolates are 
intracellular pathogens resistant to many of the standard antituberculosis drugs. In many cases 
this resistance is due to the low levels of drug permeation into macrophages, as many 
antibiotics are unable to traverse the cell membranes, making it difficult to achieve sufficient 
concentrations at the infection sites (24, 25). 
Nevertheless, it was not until the post-human immunodeficency virus (HIV) era, that renewed 
interest became widespread in mycobacterial diseases in the immunocompromised host. 
Several reasons for such interest are the following. First, re-emergence of TB in countries 
where this type of disease was in the way of eradication, was puzzling. Second, MOTT that 
were generally quite rarely isolated before the advent of AIDS, but represented before the 
recently used efficient antiretroviral therapies, have a considerable role in morbidity and 
mortality. This was particularly true for the M. avium complex (MAC) because these 
organisms are the single most important cause of disseminated bacterial infection in AIDS 
patients (26). Third the number of cases of infection with multiply-drug-resistant (MDR) of 
MT and MAC is increasing and this has compromised both treatment and control programmes 
worldwide. The rising prevalence of MDR strains has resulted in outbreaks and individual 
cases that are a problem to treat and are often fatal. Worldwide, TB and disseminated MAC 
disease, both contribute substantially to morbidity and mortality in this population. 
Among the mycobacterial genus, the vast majority of species are saprophytic belonging to the 
environmental microflora. They are present at different latitudes, and could be isolated from 
soil, and water. Mycobacteria are aerobic, Gram-positive, non-motile bacilli with a high 
mycolic acid content in their cell wall that enables intracellular survival within mononuclear 
phagocytes.  
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Figure 1.1:  
Mycobacterium Tuberculosis MT (A) and Mycobacterium Avium Complex MAC (B) 
 
Being intracellular survivors,  Mycobacteria species evoke a granulomatous to 
pyogranulomatous host response. Mycobacteria can be grouped conceptually into three 
categories: (1) obligate parasites that behave as primary pathogens and require a mammalian 
host to that comprise the tubercle bacilli (Mycobacterium tuberculosis (MTB), 
Mycobacterium bovis (MB) and Mycobacterium microti(MM)), (27, 28, 29, 30, 31); (2) 
saprophytes that can behave as facultative pathogens, causing localised or systemic disease 
depending on the degree of host compromise; these can be divided further into slow growers, 
such as the Mycobacterium avium intracellulare complex (MAC), Mycobacterium genavense 
(MG) and Mycobacterium xenopi (MX), or rapid growers, such as Mycobacterium fortuitum 
(MF), Mycobacterium chelonae (MC), Mycobacterium smegmatis (MS), Mycobacterium 
phlei (MP) and Mycobacterium thermoresistible (MTH); and (3) Mycobacteria species so 
difficult to culture that their environmental niche has not been determined with certainty, 
including Mycobacterium leprae (ML), Mycobacterium visibilis (MV),(31, 32, 33, 34, 35). 
The natural history of pathological and casual opportunist mycobacteria diseases differ due to 
different tissue tropisms: the MOTT opportunists appear to be more limited than M. 
tuberculosis in parallel with the experimental observations of more limited virulence. For 
instance, experimental infection with M. tuberculosis is often lethal in normal non-immuno-
compromised mice, in contrast virulent strains of M. avium infection are only lethal in 
immunodeficient mice (36).  
MTB was first described on 1882 by Robert Koch, and the M. Tuberculosis genome was 
sequenced (37, 38) in 1999. MTB divides every 15 to 20 hours, extremely slowly compared to 
other bacteria, which tend to have division times measured in minutes. It is a small, rod-like 
bacillus that can withstand weak disinfectants and can survive in a dry state for weeks but can 
grow only within a host organism. An important consideration in the treatment of tuberculosis 
A B 
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is the fact that the etiological agent, MTB, has the ability to persist intracellularly in the host 
macrophage for long periods of time. This becomes even more important when one considers 
the ability of MTB to persist in a dormant state, thus giving rise to a large group of infected 
individuals who carry the organism in a subclinical state without having active disease. 
The term MAC was coined after debate as to whether Mycobacterium intracellulare 
represented a distinct species or was merely a variant of M avium (39, 40, 41). Traditionally, 
the MAC has been divided into serotypes using agglutination reactions, immunodiffusion, 
skin testing with sensitins, biochemical reactions on culture, or a combination of these (41). 
Molecular techniques have more recently been used to clarify the MAC group (42, 43). M. 
avium and related species are ubiquitous, saprophytic organisms commonly found in surface 
waters such as salt or fresh-water marshes, ponds, lakes, or soil. Animals, including people, 
are commonly exposed to these organisms (41). M. avium may give rise to disease if 
introduced in sufficient numbers through a breach in the skin or via alveolar deposition. In 
immune competent hosts, such events would cause localised infections, although generalised 
disease may arise in patients with compromised cell-mediated immunity (13). 
Even though the availability of powerful anti-tubercular drugs (ATD) such as rifampicin 
(RFP), isoniazid (INH) and pyrazinamide (PZA) makes TB and MOTT infections, curable 
diseases, the latter is far from eradication, the main reason being that multiple anti-tunercular 
dugs (ATD) need to be administered for 6-9 months. Patients often find it troublesome to 
begin their day with a mouthful of pills. Further, as clinical symptoms improve, they may not 
consider the need to continue ATD and may actually forget to take the drugs. All these factors 
result in non-compliance and eventually lead to therapeutic failure. 
1.2. Alveolar Macrophages and MTB/MAC  
MTB and MAC are facultative intracellular micro-organisms that can survive and multiply 
intra-cellularly and are protected from host defence mechanism. They interact mainly with 
macrophages in the alveolar space of the lung, where they are able to invade and replicate in 
both cell types. Their intracellular location serves as reservoir which is thought to be of 
importance in recurrent infections.  
Macrophages are present in all major compartment of the body and they are particularly 
involved in removing foreign particles and micro-organism from the blood. After being 
removed from the blood, the behaviour of the micro-organism in the macrophage becomes of 
great importance. Killing of the micro-organism could mean termination of the infection, 
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whereas microbial persistence and growth in the macrophage could lead to infection in the 
organ harbouring the macrophages, and hence to current infection of the blood. 
Macrophages are found at all epithelial lung surfaces but are far more frequent in the deeper 
regions of the lung (44). The number of macrophages in the lung is variable and can be raised 
on exposure to certain materials, for example cigarette smoke (45, 46, 47). In the normal 
human lung, however, macrophages comprise of over 95% of the mobile cell population and 
account for 2–5% of the total alveolar cells numbering between 50 and 100 per alveolus (45, 
48).  
Macrophages are normal motile residents of the airways, interstitial matrix, and alveolar 
regions of the lungs (49). Particles deposited in the alveolar region are taken up rapidly by 
macrophages.  Phagocytic times of a few minutes (50) up to an hour (51) have been reported. 
The contribution of pulmonary endocytosis to the overall lung clearance is determined by the 
particle size and particle shape, (52) solubility, particle burden, (53, 54) and the chemical 
nature of the inhaled aerosol. Alveolar macrophage-mediated clearance is a much slower 
process than mucociliary clearance, with retention half-times in the range of 50–80 days in 
rats and about 10 times longer in humans (55). Particle phagocytosis by alveolar macrophages 
can be: 1) fast and efficient (titanium dioxide, diameter < 0.2 mm), 2) not efficient (ultrafine 
particles), 3) incomplete (long fibers cannot be completely phagocytized by a spherical cell 
with a diameter of approximately 12 mm), or 4) overloaded (ie, when particles occupy a large 
fraction of the volume of individual alveolar macrophages) (56). Alveolar macrophages can 
clear particles from the alveolar region in 4 ways: 1) transport along the alveolar surface to 
the mucociliary escalator, 2) internal enzymatic degradation, 3) translocation to the tracheo-
bronchial lymph, and/or 4) combination of the interstitial lymphatic route and mucociliary 
transport. It is believed that translocation of particle-laden macrophages to the mucociliary 
region is responsible for the initial rapid clearance of insoluble particles in the first 24 hours 
after deposition (57). The enzymatic activity following phagocytosis by alveolar macrophages 
is well known (58, 59) and its contribution to the overall pulmonary clearance requires 
consideration for enzyme-sensitive compounds such as biomolecules. Lung surfactant may 
cause large molecules to aggregate, which could enhance ingestion and digestion by alveolar 
macrophages (60).  
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1.3. Lung Anatomy 
The lung is the body’s organ of respiration. The respiratory tract can be divided into upper 
and lower airways, with the line of division being the junction of the larynx and trachea (61).  
 
 
Figure 1.2: The Anatomy Of Human Lungs 
 
The upper airways or nasopharyngeal region consists of the nose, mouth, larynx, and pharynx. 
Below the contours of the nasopharyngeal region, the lower airways resemble a series of tubes 
undergoing regular dichotomous branching (62). Successive branching from the trachea to the 
alveoli reduces the diameter of the tubes, but markedly increases the surface area of the 
airways, which allows gas exchange (63, 64). The lower airways can be divided into 3 
physiologic zones: conducting, transitional, and respiratory zones (62, 65). The conducting 
zone consists of the larger tubes responsible for the bulk movement of air and blood. In the 
central airways, air flow is rapid and turbulent and no gas exchange occurs. The transitional 
zone plays a limited role in gas exchange. The epithelial layer of the trachea and main bronchi 
is made up of several cell types, including ciliated, basal, and goblet. On the surface of the 
epithelium of the proximal respiratory tract, ciliated cells predominate. A large number of 
mucus-producing and serum-producing glands are located in the submucosa.  
The human lung consists of 5 lobules and 10 bronchopulmonary segments. Arranged adjacent 
to each segment are lung lobules composed of 3–5 terminal bronchioles. Each bronchiole 
supplies the smallest structural unit of the lung, the acinus, which consists of alveolar ducts, 
alveolar sacs, and alveoli. Alveolar epithelial type I cells represent the principle cell type 
lining the surface of the alveoli. The major functions of these cells, which cover 93% of the 
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alveolar space, are to provide a surface for gas exchange and to serve as a permeability 
barrier. Alveolar epithelial type II cells have a much smaller surface area per cell and they 
represent 16% of the total cells in the lung. They play a basic role in synthesis, secretion and 
recycling of surface-active material (lung surfactant). 
The alveolar blood barrier in its simplest form consists of a single epithelial cell, a basement 
membrane, and a single endothelial cell. While this morphologic arrangement readily 
facilitates the exchange, it can still represent a major barrier to large molecules. Before 
entering the systemic circulation, solutes must traverse a thin layer of fluid, the epithelial 
lining fluid. This layer tends to collect at the corners of the alveoli and is covered by an 
attenuated layer of surfactant. 
 
 
Figure 1.3: Lung Surfactant Composition 
 
Unlike the larger airways, the alveolar region is lined with a surface active layer consisting of 
phospholipids (mainly phosphatidylcholine and phosphatidylglycerol) (66) and several key 
apoproteins (67). The surfactant lining fluid plays an important role in maintaining alveolar 
fluid homeostasis and permeability, and participates in various defence mechanisms. Recent 
studies suggest that the surfactant may slow down diffusion out of the alveoli (68, 69). The 
respiratory airways, from the upper airways to the terminal bronchioles, are lined with a 
viscoelastic, gel-like mucus layer 0.5–5.0 mm thick (70). The secretion lining consists of two 
layers: a fluid layer of low viscosity, which surrounds the cilia (periciliary fluid layer), and a 
more viscous layer on top, the mucus (71). The mucus is a protective layer that consists of a 
complex mixture of glycoproteins released primarily by the goblet cells and local glands (72). 
The mucus blanket removes inhaled particles from the airways by entrapment and 
mucociliary transport at a rate that depends on viscosity and elasticity (73). The lung tissue is 
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highly vascularized, which makes pulmonary targeting difficult because of fast absorption of 
most drugs (especially lipophilic and low molecular weight drugs). 
1.4. Pulmonary Drug Delivery Following Aerosol Therapy  
There are several advantages in delivering drugs, such as antimicrobial agents, to the lungs 
including a non invasive method of delivery; a large surface area for absorption (~75m2); thin 
(0.1 to 0.5 µm) alveolar epithelium, permitting rapid absorption; absence of first-pass 
metabolism; rapid onset of action; and high bioavailability. 
Since the advent of nebulizer therapy in 1859, nebulizers have been used to treat a range of 
pulmonary diseases in pediatric and adult populations, including asthma, chronic obstructive 
pulmonary disease (COPD), and cystic fibrosis (CF).The expansion of nebulizer therapy in 
the mid to late 20th century for common respiratory diseases has been followed by a focus on 
use for more specific indications and certain new applications. 
The development of an inhalant therapy that is efficacious and safe depends not only on a 
pharmacologically active molecule, but also on a well-designed delivery system and 
formulation. It is the optimization of the whole system (drug, drug formulation and device) 
that is necessary for the successful development of inhalation therapies, both new and old, for 
the treatment of local and systemic diseases. Drug–device combinations must aerosolize the 
drug in the appropriate particle size distribution and concentration to ensure optimal 
deposition and dose in the desired region of the lung.  
Although the traditional form of inhalation therapy dates back to the earliest records of 
ancient cultures, the advantages of inhalation therapy have essentially remained the same. 
Several studies (1–3) have demonstrated the clinical advantage of inhalation aerosols over 
systemic therapy for the treatment of lung disorders. Relatively small doses are required for 
effective therapy, reducing systemic exposure to drug and thus minimizing adverse effects. 
Delivering small doses of active ingredients directly to the lung effectively targets the drug, 
thereby maximizing therapeutic effect while minimizing adverse effects. 
1.4.1. Delivery Device: Jet Nebulizer 
Nebulizers have been used for many years to treat asthma and other respiratory diseases. 
There are two basic types of nebulizer, jet and ultrasonic nebulizers. Ultrasonic nebulizers 
utilize high frequencies to convert liquid into a fine mist (74). 
1. General Introduction 
 
 
 
 
19 
The jet nebulizer functions by the Bernoulli principle by which compressed gas (air or 
oxygen) passes through a narrow orifice creating an area of low pressure at the outlet of the 
adjacent liquid feed tube. This results in drug solution being drawn up from the fluid reservoir 
and shattered into droplets in the gas stream. Jet nebulizers produce smaller droplets than do 
pMDIs, and these smaller droplets penetrate more easily to the small airways (74). 
 
 
Figure 1.4: Jet-Nenulizer Device 
 
The choice of a proper nebulizer system is very crucial for the efficient delivery of 
aerosolized respiratory drugs (75). Jet nebulizers are widely used, because of their durability, 
ease of maintenance, and availability at low cost. In a jet nebulizer, compressed air is forced 
through a narrow orifice, which leads to a decrease in lateral pressure, thereby drawing up 
liquid from the feed tube. The primary droplets are produced in the nozzle region and then 
broken down into smaller droplets. The non-respirable droplets are removed by baffles (76). 
The droplets may increase in diameter because of condensation of water vapor. This 
condensation occurs because the droplets are at a low temperature (about 10°C) after being 
released from the nebulizer, if the surrounding air stream was unsaturated (77). 
Fewer than 0.5% of the resultant droplets are small enough to leave the nebulizer; the larger 
droplets drip back into the liquid to start the process again. Size distribution data for jet 
nebulizers come from a number of studies (78, 79, 80, 81, 82, 83). These kind of nebulizer are 
able to produce, from physiologically isotonic saline, initial droplets with aerodinamic 
diameter from 1.6 to 4.9 µm. 
The size distribution of aerosol droplets from a jet nebulizer depends on the diameter of the 
liquid inlet orifice, the air velocity at the nozzle, and the ratio of the mass flow rate of air to 
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liquid (84). The droplets at the nebulizer outlet become smaller with increasing air velocity 
and increasing ratio of the mass flow rate of air to liquid. Increasing the nebulizer flow rate 
increases the aerosol output rate (78). The formation of droplets depends on the proper 
alignment and placement of the jet nozzle, liquid inlet, and impaction surface; many 
nebulizers have baffles to remove larger particles by impaction. Thus, the internal orientation 
and geometry of the jet nebulizer is critical to maintaining a reproducible output and size 
distribution. The output and size distribution are also affected by droplets' impacting and 
settling onto the tubing downstream of the nebulizer (79). Other factors that in some 
situations affect the droplet size are the gas density and the liquid surface tension and 
viscosity (84). The solution concentration itself has no effect on the size distribution of the 
droplets except to the extent that it changes the physical characteristics of the solution (78, 
80). The nebulizing action causes continual reflux of a large volume (and surface area) of 
water, which promotes extensive water evaporation. Evaporative losses from the solution can 
be decreased by using air from a compressor, which supplies air  at ambient humidity, rather 
than from a compressed gas cylinder, which supplies air that is totally dry. In summary, the 
size and solute concentration of droplets are affected by any difference in vapor pressure 
between the droplet and the surrounding air and the time available for equilibration. Thus 
gradients of relative humidity and temperature do affect the droplets and can cause the solute 
concentration in the droplets to be different from that of the nebulized fluid (80, 85). 
1.4.2. Mechanism of Drug Deposition 
Drugs for inhalation therapy are administered in aerosol form. The ability of the aerosolized 
drug to reach the peripheral airways is a prerequisite for efficacy. The regional pattern of 
deposition efficiency determines the specific pathways and rate at which deposited particles 
are ultimately cleared and redistributed (86). The pathology of disease of the lungs may 
considerably affect aerosol deposition. Patients with airway obstruction (eg, emphysema, 
asthma, chronic bronchitis) who inhaled radiolabeled aerosol showed increased central 
(tracheobronchial) deposition and diminished penetration to the peripheral pulmonary regions 
(87). The mechanisms by which particles deposit in the respiratory tract include impaction 
(inertial deposition), sedimentation (gravitational deposition), brownian diffusion, 
interception, and electrostatic precipitation (86, 88, 89). The relative contribution of each 
depends on the characteristics of the inhaled particles, as well as on breathing patterns and 
respiratory tract anatomy. All mechanisms act simultaneously, but the first two mechanisms 
are most important for large-particle deposition within the airways (1 mm , MMAD , 10 mm). 
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Diffusion, however, is the main determinant of deposition of smaller particles in peripheral 
regions of the lung (90).  
Impaction occurs when a particle’s momentum prevents it from changing course in an area 
where there is a change in the direction of bulk air flow. It is the main deposition mechanism 
in the upper airways, and at or near bronchial branching points. The probability of impaction 
increases with increasing air velocity, breathing frequency, and particle size (91, 86, 88).  
Sedimentation results when the gravitational force acting on a particle overcomes the total 
force of the air resistance. Inspired particles will then fall out of the air stream at a constant 
rate (92). This is an important mechanism in small airways having low air velocity. The 
probability of sedimentation is proportional to residence time in the airway and to particle 
size, and decreases with increasing breathing rate.  
Diffusion occur when the collision of gas molecules with small aerosol particles exerts 
discrete non-uniform pressures at the particles’ surfaces, resulting in random brownian 
motion. The effectiveness of brownian motion in depositing particles is inversely proportional 
to particle diameters of those particles, 0.5 µm, (93) and is important in bronchioles, alveoli, 
and at bronchial airway bifurcations. Molecule-size particles may deposit by diffusion in the 
upper respiratory tract, trachea, and larger bronchi.  
1.4.3. Factors Controlling Respiratory Drug Deposition 
The factors that control drug deposition are: 
(1) characteristics of the inhaled particles, such as size, distribution, shape, electrical charge, 
density, and hygroscopicity,  
(2) anatomy of the respiratory tract, and  
(3) breathing patterns, such as frequency, tidal volume, and flow.  
Of these factors, aerosol particle size and size distribution are the most influential on aerosol 
deposition.  
The size of the particles is a critical factor affecting the site of their deposition, since it 
determines operating mechanisms and extent of penetration into the lungs (94). Aerosol size 
is often expressed in terms of aerodynamic diameter (AD). The aerodynamic diameter is 
defined as the equivalent diameter of a spherical particle of unit density having the same 
settling velocity from an air stream as the particle in question (91). Thus, particles that have 
higher than unit density will have actual diameters smaller than their AD. Conversely, 
particles with smaller than unit density will have geometric diameters larger than their AD. 
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Aerosol size distributions may be characterized as practically monodisperse (uniform sizes) or 
polydisperse (nonuniform sizes).  
The upper airways (nose, mouth, larynx, and pharynx) and the branching anatomy of the 
tracheobronchial tree act as a series of filters for inhaled particles. Thus, aerosol particles 
bigger than 100 µm generally do not enter the respiratory tract and are trapped in the 
naso/oropharynx. Particles bigger than 10 µm will not penetrate the tracheobronchial tree. 
Particles must generally be smaller than 5 µm in order to reach the alveolar space (92, 94, 95). 
On the other hand, particles smaller than 0.5 µm in diameter penetrate the lung deeply, but 
have a high tendency to be exhaled without deposition.  
 
 
 
Figure 1.5: Particle Size And Sites Of Their Deposition 
1.4.4. Respiratory Tract Anatomy 
Airway geometry affects particle deposition in various ways. For example, the diameter sets 
the necessary displacement by the particle before it contacts an airway surface, cross-section 
determines the air velocity for a given flow, and variations in diameter and branching patterns 
affect mixing between tidal and reserve air (91). In contrast to many species of laboratory 
animal, humans have large lungs, a more symmetrical upper bronchial airway pattern, and are 
not obligate nose breathers. These anatomical differences produce greater amounts of upper 
bronchial particle deposition in humans (96).  
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1.4.5. Respiratory Patterns 
The pattern of respiration during aerosol exposure influences regional deposition, since 
breathing volume and frequency determine the mean flow rates in each region of the 
respiratory tract, which, in turn, influence the effectiveness of each deposition mechanism 
(91, 97, 98, 99). Turbulence tends to enhance particle deposition, the degree of potentiation 
depending on the particle size. Rapid breathing is often associated with increased deposition 
of larger particles in the upper respiratory tract, while slow, steady inhalation increases the 
number of particles that penetrate to the peripheral parts of the lungs (100). Slow breathing, 
with or without breath-holding, showed a broad maximum deposition in the ciliated airways 
(tracheobronchial region). The pulmonary maximum occurred between 1.5 µm and 2.5 µm 
with breath-holding and between 2.5 µm and 4µm without breath-holding. Rapid inhalation 
showed similar trends: the tracheo-bronchial region maximum falls and shifts to between 3 
µm and 6 µm. Pulmonary deposition sharpens and occurs between 1.5 µm and 2 µm with 
breath-holding, and between 2 µm and 3 µm without breathholding. When the above 
considerations are taken into account, the ideal scenario for aerosol would be: (1) aerosol AD 
smaller than 5 µm, to minimize oropharyngeal deposition, (2) slow, steady inhalation, and (3) 
a period of breath-holding on completion of inhalation.  
1.4.6. Pulmonary Clearance 
The primary function of the pulmonary defensive response to inhaled particles is to keep the 
respiratory surfaces of the alveoli clean and available for respiration. The elimination of 
particles deposited in the lower respiratory tract serves an important defence mechanism to 
prevent potentially adverse interactions of aerosols with lung cells. Insoluble particulates are 
cleared by several pathways, which are only partially understood. These pathways are known 
to be impaired in certain diseases and are thought to depend on the nature of the administered 
material (101, 102). Swallowing, expectoration, and coughing constitute the first sequence of 
clearance mechanisms operating in the naso/oropharynx and tracheobronchial tree.  
A major clearance mechanism for inhaled particulate matter deposited in the conducting 
airways is the mucociliary escalator, whereas uptake by alveolar macrophages (86, 103) 
predominates in the alveolar region. In addition to these pathways, soluble particles can also 
be cleared by dissolution with subsequent absorption from the lower airways. The rate of 
particle clearance from these regions differs significantly and its prolongation can have 
serious consequences, causing lung diseases from the toxic effects of inhaled compounds. It is 
now well recognized that the lungs are a site for the uptake, accumulation, and/or metabolism 
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of numerous endogenous or exogenous compounds. All metabolizing enzymes found in the 
liver are also found in the lung, although in smaller amounts. The rate at which a drug is 
cleared and absorbed from the respiratory tract  depends on the dynamic interaction of several 
factors, predominantly: (1) the mucociliary clearance rate, (2) site of deposition along the 
airways, (3) biopharmaceutical factors (particulates vs drug in solution), (4) drug release rate, 
and (5) the physicochemical properties of the drug, such as molecular weight, partition 
coefficient, and charge.  
1.4.7. Mucociliary Clearance 
Mucociliary clearance is a physiologic function of the respiratory tract to clear locally 
produced debris, excessive secretions, or unwanted inhaled particles. It consists of ciliated 
epithelial cells reaching from the naso/oropharynx and the upper tracheobronchial region 
down to the most peripheral terminal bronchioles. Beating of the cilia, together with mucus 
secreted by the goblet cells, contributes to an efficient clearance mechanism.  
For normal mucociliary clearance to occur it is necessary  that the epithelial cells are intact, 
the ciliary activity and the rheology of mucus is normal, and that the depth and chemical 
composition of the periciliary fluid layer is optimal. Thus, the mucociliary escalator can be 
impaired by altering the volume of mucus secretion, the mucus viscosity and elasticity, or the 
ciliary beat frequency. Mucociliary clearance is known to be impaired in smokers (104), in 
patients with chronic bronchitis (102), and in acute asthmatics (105). Certain diseases have 
the opposite effect that of enhancing clearance rates (106).  
1.5. Rifampicin 
Each year, there are 8–10 million new cases of TB, which is the leading cause of death in 
adults by an infectious agent (107, 108).  
Rifampicin (RFP), 3-(4-methyl-l-piperazinyl-irninomethyl) rifamycin (109, 110) is one of the 
most potent and broad spectrum antibiotics against bacterial pathogens and is a key 
component of anti-TB therapy. The introduction of RFP in 1968 greatly shortened the 
duration of TB chemotherapy. RFP diffuses freely into tissues, living cells, and bacteria, 
making it extremely effective against intracellular pathogens like M. tuberculosis (108). 
However, bacteria develop resistance to RFP with high frequency, which has led the medical 
community in the United States to commit to a voluntary restriction of its use for treatment of 
TB or emergencies. 
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RFP is an amphiphilic compound. It is extensively recycled in the enterohepatic circulation, 
and metabolites formed by deacetylation in the liver are eventually excreted in the faeces.  
 
Figure 1.6: Chemical Structure of Rifampicin.  
 
The bactericidal activity of RFP stems from its high affinity binding to, and inhibition of, the 
bacterial DNA-dependent RNA polymerase (RNAp) (111). The essential catalytic core RNAp 
of bacteria (subunit composition α2ββ’ϖ) has a molecular mass of around 400 kDa and is 
evolutionarily conserved among all cellular organisms (112). 
Mutations conferring RFP resistance map almost exclusively to the rpoB gene (encoding the 
RNAp β -subunit) in every organism tested, including E. coli (113, 114, 115) and M. 
tuberculosis (116, 117). Comprehensive genetic analyses have provided molecular details of 
amino acid alterations in β conferring RFP resistance (118, 119, 120, 121, 122, 123). 
Variable bioavailability of RFP from separate as well as fixed dose combination  formulations 
has been perceived as a major bottleneck in successful treatment of TB (124). In each 
formulations important factor that may affect rate and/or extent of dissolution is physical 
characteristics of rifampicin raw material such as polymorphic form, particle size, etc., which 
in turn have a direct impact on drug substance processability, drug product manufacturability, 
and quality of dosage forms, including stability, dissolution, and bioavailability (125). 
Therefore, a complete physical characterization and its biopharmaceutic implication is 
essential in order to determine the influence of polymorphism/physical form on 
bioavailability. RFP due to its complex structure exhibits polymorphism and exists in two 
polymorphic forms (126). It also exists as hydrates and various solvates, which eventually 
convert into amorphous form at room temperature or after desolvation (127). 
RFP is well tolerated by most patients at currently recommended doses, although 
gastrointestinal tolerance can be unacceptably severe. Other adverse effects (skin rashes, 
fever, influenza-like syndrome and thrombocytopenia) are more likely to occur with 
Formula: C43H58N4O12; 
Molecular Weight: 822.95. 
Log P: 4,24 
pKa 1: 1,7 
pKa 2: 7,9 
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intermittent administration. Exfoliative dermatitis is more frequent in HIV-positive TB 
patients. Temporary oliguria, dyspnoea and haemolytic anaemia have also been reported in 
patients taking the drug three times weekly. These reactions usually subside if the regimen is 
changed to one with daily dosage. However, dose-related hepatitis can occur which is 
potentially fatal.  
RFP induces hepatic enzymes, and may increase the dosage requirements of drugs 
metabolized in the liver. These include corticosteroids, steroid contraceptives, oral 
hypoglycaemic agents, oral anticoagulants, phenytoin, cimetidine, cyclosporin and digitalis 
glycosides.  
1.6. Microspheres as Controlled Delivery Systems 
Drug delivery systems (DDS) that can precisely control the release rates or target drugs to a 
specific 
body site have had an enormous impact on the healthcare system. The last two decades in the 
pharmaceutical industry have witnessed an avant-garde interaction among the fields of 
polymer and material science, resulting in the development of novel drug delivery systems 
(128). Carrier technology offers an intelligent approach for drug delivery by coupling the drug 
to a carrier particle such as microspheres, nanoparticles, liposomes, etc. which modulates the 
release and absorption characteristics of the drug.  
Conventional drug administration does not usually provide rate-controlled release or target 
specificity. In many cases, conventional drug delivery provides sharp increases of drug 
concentration at potentially toxic levels. Following a relatively short period at the therapeutic 
level, drug concentration eventually drops off until re-administration.  
Today  new methods of drug delivery are possible: desired drug release can be provided by 
rate-controlling membranes or by implanted biodegradable polymers containing dispersed 
medication. Over the past 25 years much research has also been focused on degradable 
polymer microspheres for drug delivery. Microspheres constitute an important part of these 
particulate DDS by virtue of their small size and efficient carrier characteristics. 
Administration of medication via such systems is advantageous because microspheres can be 
ingested, injected or inhaled; they can be tailored for desired release profiles and in some 
cases can even provide organ-targeted release. The idea of controlled release from polymers 
dates back to the 1960s through the employment of silicone rubber (129) and polyethylene 
(130). The lack of degradability in these systems implies the requirement of eventual surgical 
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removal and limits their applicability. In the 1970s biodegradable polymers were suggested as 
appropriate drug delivery materials circumventing the requirement of removal (131). The idea 
of polymer microspheres as delivery systems was reported as early as the 1960s (132) and 
degradation was incorporated by Mason et al. (133) through the employment of a degradable 
polymer. 
Recent literature shows that suspensions of degradable microspheres can be employed for 
sustained drug release at desirable doses. Biocompatibility can be achieved by the use of 
natural polymers such as cellulose, chitin, and chitosan or by the employment of semisyntetic 
polymers made from naturally occurring monomers such as lactic and glycolic acids. 
Polymers derived from synthetic monomers also show excellent delivery properties. 
However, their toxicity effects may require evaluation. The factors affecting drug release are 
controllable; they are attributed to properties such as polymer molecular weight, as well as 
microsphere size, distribution, morphology and make-up. 
For preparation of microspheres using biodegradable polymers, it is important to choose an 
appropriate encapsulation process which meets the following requirements. First, the 
chemical stability and biological activity of the incorporated drugs should be maintained 
during the encapsulation process. For example, since most proteins are readily denatured upon 
contact with hydrophobic organic solvents or acidic/basic aqueous solutions, the process 
should avoid such harsh 
environments. Second, the encapsulation efficiency and the yield of the microparticles should 
be high enough for mass production. Third, the microparticles produced should have the 
reasonable size range. Fourth, the release profile of the drug should be reproducible without 
the significant initial burst. Fifth, the process employed should produce free-flowing 
microparticles, thus making it easy to prepare uniform suspension of the microparticles. There 
are a number of techniques available for microencapsulation of drugs such as the emulsion-
solvent evaporation/extraction method, spray drying, phase separation-coacervation, 
interfacial deposition, precipitation method, in situ polymerization, etc. Each method has its 
own advantages and disadvantages. The choice of a particular technique depends on the 
attributes of the polymer and the drug, the site of the drug action, and the duration of the 
therapy (134, 135, 136). 
Increasing or controlling the encapsulation efficiency (E%) is desirable, it can prevent the loss 
of precious medication and it can help to extend the duration and dosage of treatment. Yang et 
al. (137) have provided a revealing study which correlated the encapsulation efficiency to 
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sphere preparation temperature. The authors found that the highest encapsulation efficiencies 
occurred at the lowest and highest formation temperatures tested (about 50% at 4 and 38°C, 
and about 19% at 22 and 29°C). The non-linear drug loading trend suggested that different 
mechanisms governed the encapsulation process at different temperatures. When considering 
the relation of the polymer itself to encapsulation efficiency, Ghaderi et al. (138) found that 
increasing the concentration of polymer in the organic phase increased the encapsulation 
efficiency. An increase in E% from 1 to 25% was observed depending on the concentration of 
the polymer.  
Microsphere size can be affected by the polymer concentration, temperature, viscosity, the 
stirring rate, and the amount of emulsifier employed. Considering the effect of polymer 
concentration, it has often been reported that increasing the concentration of polymer 
increases sphere size (138, 139, 140, 141, 142). Yang et al. (137) used scanning electron 
microscopy (SEM) to show that sphere size was temperature dependent; lower and higher 
temperatures produced larger spheres whereas intermediate temperatures produced smaller 
spheres. Once again, different mechanisms dominated microsphere formation at different 
temperatures. At lower temperatures, the solution’s higher viscosity resulted in the formation 
of larger spheres; this has also been confirmed by other researchers (143). Larger spheres 
were obtained at higher temperatures due to the higher rate of solvent evaporation which 
resulted in higher solvent flow pressure moving more material from the sphere center outward 
(137). 
Jalil and Nixon (144) studied the variation of sphere size with respect to the stirring rate and 
the influence of the emulsifier in the second emulsion step. It was shown that microsphere 
size decreased with increasing stirring rate since increased stirring results in the formation of 
finer emulsions. Little change in diameter size was reported by varying emulsifier 
concentration. 
Controlled release is an attainable and desirable characteristic for DDS. The factors affecting 
the drug release rate revolve around the structure of the matrix where the drug is contained 
and the chemical properties associated with both the polymer and the drug. Conventional oral 
delivery is not rate controlled. A drug encapsulated in a slowly degrading matrix provides the 
opportunity for slower release effects, but polymer degradation is not the only mechanism for 
the release of a drug. The drug release is also diffusion controlled as the drug can travel 
through the pores formed during sphere hardening. In some cases, drugs containing 
nucleophilic groups can cause increased chain scission of the polymer matrix, which also 
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increases the rate of drug expulsion. Polymer molecular weight, drug distribution, polymer 
blending, crystallinity, and other factors are important in manipulating release profiles. The 
most desirable release profile would show a constant release rate with time. However, in 
many cases release profiles are more complicated and often contain two main expulsion 
processes: the first being an initial burst of expelled medication from the sphere surface; the 
second, a usually more constant stage with release rates dependent on diffusion and 
degradation (145, 146, 147). 
The release profiles are also dependent on the size of the microspheres; the rate of drug 
release was found to decrease with increasing sphere size (148, 149, 150, 151, 152). 
Therefore, by mixing microspheres of different sizes it is possible to obtain another degree of 
controlling release. More importantly, linear, zero-order kinetics are obtainable by combining 
the proper formulation of microsphere sizes. 
Core-shell microspheres usually refer to spheres formed by making core units through a 
normal preparative method, followed by the addition of an outer layer by a dipping procedure, 
mixing procedure, or emulsion procedure (153, 154, 155, 156, 157, 158). Employment of a 
shell is usually meant to enhance controlled release and possibly reduce the effect of the 
initial burst. 
1.7. Bioadhesive Microspheres as Systems Able to Enhance 
Pulmonary Drug Delivery 
The success of microspheres as  DDS is limited due to their short residence time at the site of 
absorption. It would, therefore, be advantageous to have means for providing an intimate 
contact of the DDS with the absorbing membranes. It can be achieved by coupling 
bioadhesion characteristics to microspheres and developing novel delivery systems referred to 
as “bioadhesive microspheres”. 
“Bioadhesion” in simple terms can be described as the attachment of a synthetic or biological 
macromolecule to a biological tissue. An adhesive bond may form with either the epithelial 
cell layer, the continuous mucus layer or a combination of the two. The term “mucoadhesion” 
is used specifically when the bond involves mucous coating and an adhesive polymeric 
device, while “cytoadhesion” is the cell-specific bioadhesion. Bioadhesive microspheres 
include microparticles and microcapsules (having a core of the drug) of 1–1000 µm in 
diameter and consisting either entirely of a bioadhesive polymer or having an outer coating of 
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it, respectively (159). Microspheres, in general, have the potential to be used for targeted and 
controlled release drug delivery; but coupling of bioadhesive properties to microspheres has 
additional advantages, e.g. efficient absorption and enhanced bioavailability of the drugs due 
to a high surface to volume ratio, a much more intimate contact with the mucus layer, specific 
targeting of drugs to the absorption site achieved by anchoring plant lectins, bacterial adhesins 
and antibodies, etc. on the surface of the microspheres. Microspheres prepared with 
bioadhesive and bioerodible polymers undergo selective uptake by the macrophages cells in 
lung mucosa and by the M cells of Peyer patches in gastrointestinal (GI) mucosa. Bioadhesive 
microspheres offer unique carrier system for many pharmaceuticals and can be tailored to 
adhere to any mucosal tissue, including those found in eyes, oral cavity and throughout the 
respiratory, urinary and gastrointestinal tract. 
Increased residence time of particulate delivery systems at the mucosal surface may facilitate 
the increased uptake of such particlres. To this end, muco- or bioadhesive agents provide a 
strategy that may help to increase the residence time and, hence, the uptake of biodegradable 
particulate when administered by the pulmonary routes.  
Agents such as hydroxypropylcellulose (HPC) (160, 161), chitosan (162), carbopol (163), 
carboxymethylcellulose, hyaluronic acid and polyacrylic acid (164) have all shown promise 
as muco/bio-adhesive agents for potential use in pulmonary delivery, either alone, in 
combination with another carrier or incorporated into the structure of the carrier itself (165).  
1.8. Microspheres for Inhalation 
Aerosolised administration of drugs to the lung has been employed for many years to treat 
primarily localised disease states within the bronchi. Since this route of administration can 
deliver therapeutic agents to the diseased regions whilst reducing their distribution to the other 
organs, it provides an excellent example of targeted drug therapy. Hence, a more favourable 
therapeutic index can be obtained for the treatment of lung diseases when drugs are 
administered by inhalation rather than by the oral route. Bronchodilators, anti-inflammatory 
agents, mucolytics, antiviral agents, anticancer agents and phospholipidprotein mixtures for 
surfactant replacement therapy are all routinely given as aerosolised formulations whilst more 
recently, there has been an increasing interest in the delivery of drugs via the lung to treat 
pulmonary deseases in particular these associated with AIDS. Moreover, the development of 
potent protein drugs by biotechnology has also stimulated a growth of interest in inhalation 
aerosols because of the possibility of systemic delivery of these drugs via the airways (166). 
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A significant disadvantage of many existing inhaled drugs is the relatively short duration of 
resultant clinical effects and most medications in aerosol form require inhalation at least 3-4 
times daily (167). This often leads to poor patient compliance with the therapeutic regime and 
increases the possibility of associated side effects due to the risk of self-administration of the 
drug by the patients. A reduction in the frequency of dosing would be convenient, particularly 
for chronic treatments such as those for asthma. Sustained release of such drugs in the lung 
would be particularly beneficial since they could be delivered to and retained at the targeted 
receptors for a prolonged period of time and thus minimise the biodistribution throughout the 
systemic circulation.  
The potential advantages of achieving sustained release to the lung has been shown by the 
improved therapeutic effects obtained with a corticosteroid inhaled four times a day compared 
to two times a day (168). Controlled release of drugs within the pulmonary tree also offers 
many distinct advantages for agents which are administered for systemic actions. Many of 
these, in the future, are likely to be potent proteins and peptides designed to regulate 
important biological responses (169) and the pulmonary route provides many potential 
advantages compared to other portals of delivery. Currently, a number of methods have been 
investigated as potential pulmonary sustained-release systems for short-acting drugs. These 
include the incorporation of drugs in liposomes and in particular in biodegradable 
microspheres. 
The use of controlled release polymeric systems is an approach that holds promise for 
improving the duration and effectiveness of inhaled drugs, for both local and systemic action 
(170).  
Initial studies with polymeric aerosol systems showed that properly engineered, large porous 
particles (LPP) were also capable of delivering bioactive insulin to the blood of rats and 
control glucose levels for 96 h. The previous longest sustained delivery of insulin to the blood 
via the lungs was only 6 h, using liposomes that were intratracheally instilled into rat lungs. 
Since then, only limited examples of polymeric aerosol systems have been reported. For 
example, cationic polymers, such as polyethyleneimine (PEI) and poly-l-lysine (PLL), 
complexed with DNA have also been tested in the airways as a method to achieve transient 
gene expression.  
For example albumin microspheres can be prepared by either physical denaturation or 
chemical cross-linking of albumin droplets. The role of albumin microspheres as drug 
delivery systems for targeted and sustained release after intravenous administration has been 
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the subject of extensive research. Some of these studies have been conducted with the 
intention of targeting drugs selectively to the lung (171). However, the biodegradability, lack 
of toxicity and immunogenicity, ready availability and capability to undergo chemical 
modification could render them suitable as a carrier for inhalation of drugs. The possibility of 
using drug-containing albumin microspheres (172) as an inhaled dry powder was also 
investigated, employing similar preparation and in vitro evaluation procedures (173). 
Tetrandrine, an antisilicotic alkaloid, was entrapped in albumin microspheres and factorial 
design employed to optimise particle size and drug entrapment. The tetrandrine recovered 
from the lower stage of a twin-stage liquid impinger operated under the pharmacopoeial 
conditions was 13.83 ± 2.58% (n = 6) and such levels were considered sufficient for 
therapeutic efficiency. Thus, albumin microspheres have the potential to deliver tetrandrine to 
the alveolar region where they may be metabolised to incorporate the drug in alveolar 
macrophages, which are thought to be the main site of action of tetrandrine.  
Also PGL microspheres as a successful drug delivery system, have been used for targeting 
and controlled release of a wide range of drugs, including peptides and proteins (174). Their 
potential use in pulmonary delivery has also been explored. Masinde and Hickey (175) were 
able to prepare poly(lactic acid) (PLA) microspheres with particle sizes between 1 and 11µm 
by a solvent evaporation technique. After suspending the microspheres in a non-surfactant 
solution this was subsequently atomised by a jet nebulizer, particles were generated which 
were suitable for drug delivery to the lower airways, having a median diameter of 2 µm and 
geometric standard deviation of 2.4/zm. Sustained bronchodilation was reported by Lai et al. 
(176) after PGL microspheres with a mean diameter of 4.5/zm containing entrapped 
isoproterenol (7% w/w) were intratracheally administered to Long-Evans rats. Even though 
70% of the incorporated isoproterenol had been released from the MS into the instillation 
medium prior to administration, the drug still significantly ameliorated serotonin-induced  
bronchoconstriction for more than 12 h at a dose of 0.1 mg kg -1.  
The use of polymeric microparticles to deliver anti-tubercular drugs (ATDs) by different 
routes (injectable, oral and aerosol) has been reported by several investigators. In recent years, 
one of the best ways to achieve higher drug levels in the lungs has been the development of 
new formulations (microparticle-based) that are directly delivered to the lungs via the aerosol 
route. 
For example, several groups have investigated respiratory delivery of microsphere-
encapsulated antibiotics for the local treatment of tuberculosis (177, 178). It has been 
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observed that particles reaching the lungs are phagocytosed rapidly by alveolar macrophages. 
Although phagocytosis and sequestration of inhaled powders may be a problem for drug 
delivery to other cells comprising lung tissue, it is an advantage for chemotherapy of TB. 
Phagocytosed microparticles potentially can deliver larger amounts of drug to the cytosol than 
oral doses. Moreover, microparticles have the potential for lowering dose frequency and 
magnitude, which is especially advantageous for maintaining drug concentrations and 
improving patient compliance. It may therefore be advantageous to incorporate inhalable 
microparticles containing multiple drugs in a inhalation system for chemotherapy of TB. 
Because of its biodegradability and biocompatibility, poly (lactide-co-glycolide) (PLGA; a 
synthetic polymer) has been a popular choice as a drug carrier. Patrick O’Hara et all. by 
employing solvent evaporation as well as spray drying methods, PLGA microparticles 
encapsulating rifampicin were prepared (179). The microspheres were administered via 
insufflation or nebulization to guinea pigs, 24 h before aerosol infection with M. tuberculosis 
H37Rv. The model was adopted as a post-treatment screening method for antimicrobial 
efficacy. The assessment of colony forming units (cfu) 28 days post-infection showed a dose–
effect relationship, i.e. lower cfu with higher doses of microspheres. The cfu count was 
significantly reduced compared with free rifampicin. With a similar experimental approach, 
the authors next evaluated the effect of repeated dosing of the microspheres. At 10 days post-
infection, half of the treatment group received a second dose of the microspheres. There was a 
significant reduction in cfu in lungs (but not in spleens) in the case of animals receiving a 
single dose of the formulation, whereas two doses resulted in a significant decrease in cfu in 
lungs as well as in spleens. It was realized that besides the methodology involved in 
microparticle preparation, the surface characteristics of dry powders also play a key role in 
predicting particle dispersion and pulmonary deposition. Although the results with rifampicin-
loaded microspheres proved to be encouraging, it was necessary to incorporate other ATDs 
because the disease requires multidrug therapy for its cure. Hence, other investigators 
encapsulated isoniazid with rifampicin in polylactide microparticles for dry powder inhalation 
to rats. Drug concentrations inside the alveolar macrophages were found to be higher than that 
resulting from systemic delivery of free drugs, an indication of the rapid phagocytic uptake 
and cytosolic localization of the drug-loaded microparticles. The authors discussed that since 
alveolar macrophages migrate to secondary lymphoid organs, loading these cells with 
microparticles might lead to transport of drugs to those sites where macrophages migrate 
(mimicking the course of spread of mycobacteria).  
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A. zahoor et al. developped  a natural polymer-based inhalable drug delivery system to 
overcome the limitations associated with various drug delivery systems. Sodium alginate, a 
natural polymer with properties such as an aqueous matrix environment, high gel porosity and 
biocompatibility, and approved by the US Food and Drug Administration (FDA) for oral use 
(180, 181), was used to prepare particles encapsulating three antitubercular drugs (ATDs). 
Alginate microparticles containing isoniazid (INH), pyrazinamide (PZA) and rifampicin (RIF) 
were developed and characterised, and pharmacokinetic and pharmacodynamic evaluation 
was carried out via the aerosol route in guinea pigs. The majority of particles (80.5%) were in 
the respirable range, with mass median aerodynamic diameter of 1.1±0.4µm and geometric 
standard deviation of 1.71±0.1µm. The relative bioavailabilities of all drugs encapsulated in 
alginate particles were significantly higher compared with oral free drugs. All drugs were 
detected in organs (lungs, liver and spleen) above the minimum inhibitory concentration until 
15 days post nebulization, whilst free drugs stayed up to day 1. The chemotherapeutic 
efficacy of three doses of drug-loaded alginate nanoparticles nebulised 15 days apart was 
comparable with 45 daily doses of oral free drugs. Thus, inhalable alginate particles can serve 
as an ideal carrier for the controlled release of antitubercular drugs. 
The rising incidence of multidrug-resistant TB (MDR-TB) is a matter of great concern 
because the treatment involves the use of second-line ATDs, which are more costly and toxic 
compared with the first-line drugs used to treat drug-susceptible TB. Furthermore, the 
treatment schedule is more prolonged with a greater risk of patient non-compliance (182). 
Some of the second-line drugs, e.g. para-aminosalicylic acid (PAS), need to be administered 
in very large amounts (up to 12 g daily), which is inconvenient to the patient. In order to 
reduce the drug dosage, investigators have formulated an inhalable microparticulate system 
for PAS, based on dipalmitoylglycero-3-phosphocholine. The microparticles were produced 
by spray drying, possessed a 95% drug loading and were administered to rats via insufflation. 
The drug was maintained at therapeutic concentrations in the lung tissue for at least 3 h (the 
authors did not monitor the drug levels further) following a single dose of just 5mg of the 
dried formulation. Accelerated stability studies indicated that the formulation was stable for 
up to 4 weeks. 
Properly designed new polymeric aerosols, with the ability to target various regions of the 
lung, should prove beneficial for prolonged non-invasive treatment of both lung disorders, 
such as asthma, cystic fibrosis, mycobacteriosi and diseases requiring drug delivery to the 
systemic circulation. 
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2.1. Chitosan and Chitosan Microspheres as Controlled Delivery 
System 
Chitosan, a natural linear biopolyaminosaccharide, is obtained by alkaline deacetylation of 
chitin, which is the second abundant polysaccharide next to cellulose (183, 184). Chitin is the 
principal component of protective cuticles of crustaceans such as crabs, shrimps, prawns, 
lobsters and cell walls of some fungi such as aspergillus and mucor. Chitin is a straight 
homopolymer composed of β-(1,4)-linked N-acetyl-glucosamine units while chitosan 
comprises of copolymers of glucosamine and N-acetyl-glucosamine (185, 186, 187). Chitosan 
has one primary amino and two free hydroxyl groups for each C6 building unit.  
 
 
Figure 2.1: Chitosan Chemical Structure 
 
Due to the easy availability of free amino groups in chitosan, it carries a positive charge and 
thus in turn reacts with many negatively charged surfaces/polymers and also undergoes 
chelation with metal ions (188). Chitosan is a weak base and is insoluble in water and organic 
solvents, however, it is soluble in dilute aqueous acidic solution (pH < 6.5), which can 
convert the glucosamine units into a soluble form (R–NH3+) (189). It gets precipitated in 
alkaline solution or with polyanions and forms gel at lower pH. Commercially, chitosan is 
available in the form of dry flakes, solution and fine powder. It has an average molecular 
weight ranging between 3800 and 2,000,000 and is from 66 to 95% deacetylated (181). 
Particle size, density, viscosity, degree of deacetylation, and molecular weight are important 
characteristics of chitosan which influence the properties of pharmaceutical formulations 
based on chitosan. Properties such as biodegradability, low toxicity and good biocompatibility 
make it suitable for use in biomedical and pharmaceutical formulations (189, 190), e.g. it is 
D-Glucosamine 
N-Acetyl-D-Glucosamine 
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used for hypobilirubinaemic and hypocholesterolemic effects (191, 192), antiacid and 
antiulcer activities, wound and burn healing properties (193), immobilization of enzymes and 
living cell and in ophthalmology (194). Among pharmaceutical applications it has been used 
as a vehicle for directly compressed tablets (195, 196, 197), as a disintegrant (197), as a 
binder (198), as a granulating agent (199), in ground mixtures (200), as a drug carrier for 
sustained release preparations (201, 202, 203, 204) as well as a co-grinding diluent for the 
enhancement of dissolution rate and bioavailability of water insoluble drugs (205, 206, 207). 
Chitosan has been shown to possess mucoadhesive properties (208, 209, 210) due to 
molecular attractive forces formed by electrostatic interaction between positively charged 
chitosan and negatively charged mucosal surfaces. These properties may be attributed to: (a) 
strong hydrogen bonding groups like –OH, –COOH (211); (b) strong charges (212); (c) high 
molecular weight (213); (d) sufficient chain flexibility (209); and (e) surface energy 
properties favoring spreading into mucus (214). The positive charge on chitosan polymer 
gives rise to strong electrostatic interaction with mucus or negatively charged sialic acid 
residues on the mucosal surface. Chitosan also shows good bioadhesive characteristics and 
can reduce the rate of clearance of drug from the pulmonary system thereby increasing the 
bioavailability of drugs incorporated in it (215).  
Chitosan possess suitable properties as a carrier for microsphere drug delivery. Chitosan 
microspheres are the most widely studied drug delivery systems for the controlled release of 
drugs, antibiotics, antihypertensive agents, anticancer agents, proteins, peptide drugs and 
vaccines.  
Chitosan microspheres are used to provide controlled release of many drugs and to improve 
the bioavailability of degradable substances such as protein or enhance the uptake of 
hydrophilic substances across the epithelial layers. Chitosan has also been used as a potential 
carrier for prolonged delivery of drugs, macromolecules and targeted drug delivery. Magnetic 
chitosan microspheres used in targeted drug delivery are expected to be retained at the target 
site capillaries under the influence of an external magnetic field (216). Also, strong interaction 
between cationic microspheres and anionic glycosaminoglycan receptors can retain the 
microspheres in the capillary region (216). 
Reacting chitosan with controlled amounts of multivalent anion results in crosslinking 
between chitosan molecules. The crosslinking may be achieved in acidic, neutral or basic 
environments depending on the applied method. This crosslinking has been extensively used 
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for the preparation of chitosan microspheres. Processes used for the preparation of the 
microspheres are shown in Figure 2. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Chitosan Microspheres: Preparation Methods   
 
The entrapment efficiency of the drugs in chitosan microspheres can be affected by many 
factors, e.g. nature of the drug, chitosan concentration, drug-polymer ratio, stirring speed, etc. 
Generally a low concentration of chitosan shows low encapsulation efficiency (217). 
However, at higher concentrations, chitosan forms highly viscous solutions, which are 
difficult to process. A number of reports have shown that entrapment efficiency increases 
with an increase in chitosan concentration. A study carried out by Nishioka et al. (218) also 
revealed that the cisplatin content increased with increasing chitosan concentration. 
Microspheres made with a mixture of high molecular weight/low molecular weight chitosan 
(1:2 w/w) showed good drug content and encapsulation efficiency and these were independent 
of polymer/drug ratio.  
In an attempt to incorporate the drug onto previously formed chitosan microspheres, 
prednisolone sodium phosphate was adsorbed to previously manufactured chitosan 
microspheres (219, 220). The drug adsorption was found to be dependent upon the initial drug 
concentration. A higher initial concentration led to a higher loading efficiency. It was also 
observed that lipophilic steroids were adsorbed in lower amounts as compared to their 
hydrophilic derivatives. Hejazi and Amiji (221) prepared chitosan microspheres by ionic 
crosslinking and precipitation with sodium sulfate. Two different methods were used for drug 
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loading. In first method, tetracycline was mixed with chitosan solution before the 
simultaneous crosslinking and precipitation. In second method, the drug was incubated with 
pre-formed microspheres for 48 h. When the drug was added to the polymer solution before 
crosslinking and precipitation, only 8% (w/w) was optimally incorporated in the final 
microsphere formulation. On the other hand, when the drug was incubated with the pre-
formed microspheres, a maximum of 69% (w/w) could be loaded. This signifies that the drug 
can be adsorbed on the chitosan microspheres to a greater extent using the latter method.  
Many parameters determine the drug release behavior from chitosan microspheres. These 
include concentration and molecular weight of the chitosan, the type and concentration of 
crosslinking agent, variables like stirring speed, type of oil, additives, crosslinking process 
used, drug-chitosan ratio, etc.  
Drug release studies from chitosan microspheres have generally shown that the release of the 
drug decreases with an increase in molecular weight of chitosan. This may be attributed to 
swelling behavior of chitosan microspheres. An increase in molecular weight of chitosan 
leads to increase in viscosity of the gel layer, which influences the drug diffusion as well as 
erosion of the microspheres. Increasing the polymer concentration drug release decreases. 
A number of reports studying the effect of drug release have shown that the release of the 
drug from the microspheres increases with increase in drug content in the microspheres. 
However, different results have also been reported. Cross-linking density has a remarkable 
effect on the release of drugs from the microspheres. Jameela et al. (222) revealed that highly 
crosslinked microspheres released only 35% of the progesterone in 40 days compared to 70% 
release from microspheres cross-linked lightly. Kumar et al. (223) encapsulated curcumin 
(upto an extent of 79.49 and 39.66%) in bovine serum albumin and chitosan to form a depot 
forming drug delivery system. Microspheres were prepared by emulsion–solvent evaporation 
method coupled with chemical crosslinking of the natural polymers. The concentration of the 
crosslinking agent had remarkable influence on the drug release. In vitro release studies 
indicated a biphasic drug release pattern, characterized by a typical burst-effect followed by a 
slow release which continued for several days. Dini et al. (224) studied the synthesis and 
characterization of GA crosslinked chitosan microspheres containing hydrophilic drug, 
hydroquinone. It was found that slow drug release rates were obtained from microspheres 
prepared by using a high initial concentration of chitosan, a high molecular weight of chitosan 
or/and a low drug concentration. It was established that the release rate of hydroquinone was 
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mainly controlled by the polymer crosslinking density and the degree of swelling of the 
hydrogel matrix.  
Chitosan microspheres are very stable. In fact, only few studies have reported the instability 
of chitosan microspheres (prepared by precipitation) in acidic medium. Berthold et al. (219) 
prepared chitosan microspheres by sodium sulfate precipitation but the acid stability of the 
microspheres was found to be poor. Lather, Berthold et al. (220) made an extensive 
investigation into the acid stability of the microspheres finding that cross-linking with GA can 
improve it.  
Microparticles prepared using chitosan are being extensively investigated for various classes 
of drugs like anticancer drugs, antiinflammatory drugs, cardiac agents, antibiotics, 
antithrombotic agent, steroidal drugs, anticalcification agents, proteins, antigens, antidiabetic 
agents, growth factors,  DNA encapsulation, diuretics, central nervous system (CNS) acting 
agents, anti-infective agents, gastrointestinal agents. 
Chitosan is a versatile polymer whose applications range from weight supplement in the 
market to a drug carrier in formulation research.  
2.2. PLGA and PLGA Microspheres as Controlled Delivery 
System 
Synthetic biodegradable polymers have gained more popularity than natural biodegradable 
polymers. The major advantages of synthetic polymers include high purity of the product, 
more predictable lot-to-lot uniformity, and free of concerns of immunogenicity. During the 
last 30 years, numerous biodegradable polymers have been synthesized. Most of these 
polymers contain labile linkages in their backbone such as esters, orthoesters, anhydrides, 
carbonates, amides, urethanes, etc.  
Among the different classes of biodegradable polymers, the thermoplastic aliphatic 
poly(esters) such as poly(lactide) (PLA) and its glycolic acid copolymer poly(lactide-co-
glycolide) (PLGA) are most commonly used as drug carrier due to their excellent 
biocompatibility and biodegradability and mechanical strength (226).  
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Figure 2.3: PLGA Chemical Structure 
 
They can degrade by non-enzymatic hydrolysis of the ester backbone in body fluid. The 
degradation products (i.e. lactic and glycolic acids) are metabolic compounds (227). Most 
importantly, PLA and PLGA have been approved by the United States Food and Drug 
Administration (FDA) for drug delivery. 
The biodegradation of the PLGA occurs through random hydrolitic chain scissions of the 
swollen polymer. The cleavage of ester bond linkages yields carboxylic end groups and 
hydroxyl groups. The formed carboxylic groups then could catalyze and accelerate the 
hydrolysis of other ester bonds, a phenomenon referred as autocatalysis. The polymer erosion 
in delivery devices is the degradation of polymers to water-soluble fragments, accompanied 
by a progressive weight loss of the matrix. Generally, the polymer erosion could be classified 
into two mechanisms, namely surface or bulk erosion (228). In the case of surface erosion, the 
degradation is faster than the water diffusion. Thus the degradation and erosion take place on 
the surface of the matrix; in contrast, with bulk erosion, the water penetration is faster and the 
degradation and erosion affect all the polymer bulk. PLGA are bulk erosion polymers. The 
weight loss of the polymer devices doesn’t take place at the beginning of the degradation of 
the PLGA. Accompanying with the produced water-soluble oligomers, significant weight loss 
occurs when the molecular weight of the PLGA reaches certain threshold (229). The 
heterogeneous degradation of the large size PLGA devices has been reported recently (230). It 
was found that after subcutaneously implantation, the molecular weight of the outer phase of 
the polymer plate was higher than that of the inner phase. The outer phase was solid but the 
inner phase was sometimes semisolid (230). During the degradation of the polyester, the 
formed soluble acidic oligomers inside the matrix may not easily diffuse out, which may lead 
to a more acidic microenvironment inside the matrix. Therefore the autocatalysis is more 
prominent in the bulk than at the surface, which leads to the surface-interior differentiation. 
The physical and chemical characteristics of PLGA such as molecular weight, glass transition 
temperature, and copolymer ratios are crucial to the biodegradation behavior of the polymers. 
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At present, a numerous of analytical methodologies are introduced to characterize these 
properties, which then provide the potential clue to understand, predict and eventually modify 
the release behavior of the systems. 
The most commonly used method to analyze the molecular weight of PLGA is the size 
exclusion chromatograph (SEC). Polydispersity reveals the molecular weight distribution. 
The higher the polydispersity, the wider the molecular weight distribution is (231). 
Lactic acid contains an asymmetric carbon atom and has two optical isomers. PLA can exist 
in two stereo forms, optically active form (L-PLA) and optically inactive racemic form 
(D,LPLA). L-PLA is found to be semicrystalline in nature due to high regularity of its 
polymer chain while D,L-PLA is an amorphous polymer because of irregularities in its 
polymer chain structure. Hence the use of D,L-PLA is preferred over L-PLA as it enables 
more homogeneous dispersion of the drug in an optically inactive polymer matrix. 
Crystallinity of the PLGA can be determined by DSC or X-ray diffraction. It is directly 
related to the molecular weight, type, and molar ratio of the copolymer component. PLGAs 
prepared from L-PLA and PGA are crystalline copolymers while those from D,L-PLA and 
PGA are amorphous in nature. It was reported that PLGAs containing less than 70% glycolide 
are amorphous in nature (232). 
Glass transition temperature (Tg) is the temperature at which the polymers change from 
glassy state to rubbery state. At this point, the mechanical behavior of the polymer changes 
from rigid and brittle to tough and leathery (plastic behavior). The Tg of PLGAs is commonly 
above the physiological temperature of 37 °C, which gives them enough mechanical strength 
to be fabricated into delivery devices. The Tg of the PLGA decreases with decrease of lactic 
acid content in copolymer and with decrease in their molecular weight (233). 
Analysis of copolymer composition of PLGA can be accomplished by magnetic resonance 
spectroscopy (NMR).  
The biodegradable profiles of PLGA could be influenced by the physical and chemical 
properties of the polymer and the additives or encapsulated drugs in the polymer matrix. In 
general, the degradation rate of the PLGA decreases with the decrease of  1) polymer 
molecular weight (234); 2) initial crystallinity (235); 3) lactic/glycolic copolymer ratio (236); 
4) glass transition temperature (237); 5) hydrophilicity of the polymer 
The degradation rate increase with incorporation of  acidic or basic compounds (238) 
Microparticles based on biodegradable polymer have been extensively investigated as 
controlled release delivery system over the past three decades. In recent years, a continued 
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interest in PLGA microparticles has been triggered by their application for the controlled 
release of macromolecular drugs. Biodegradable microparticles can be prepared by several 
methods, but the most widely used techniques are phase separation (coacervation), spray 
drying, and solvent evaporation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: PLGA Microspheres: Preparation Methods 
 
The manufacturing method has much influence on the structure and release properties of the 
microparticles.  
General requirements for microparticle preparation include: 
• Maintain the stability of the encapsulated active ingredient 
• Obtain optimal drug loading, high encapsulation efficiency and yield 
• Get desired drug release profiles and low initial release 
• Involve a simple, reproducible, and scaleable process 
Generally PLGA microspheres are prepared by using oil–water emulsions that consist of an 
organic phase comprised of a volatile solvent with dissolved polymer and the drug to be 
encapsulated, emulsified in an aqueous phase containing dissolved surfactant. Two common 
examples of volatile organic solvents used for the organic-phase solvent are dichloromethane 
and ethyl acetate. A surfactant is also included in the aqueous phase to prevent the organic 
droplets from coalescing once they are formed. Once the droplets are formed via physical 
means, the organic solvent leaches out of the droplet into the external aqueous phase before 
evaporating at the water–air interface. Emulsions are simply created by using a propeller or 
magnetic bar for mixing the organic and aqueous phases. The organic-phase solvent should be 
able to dissolve the polymer up to reasonably high concentrations but does not necessarily 
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need to be a good solvent for the drug. The solvent should be completely or almost 
completely immiscible in water such that a two-phase system can be easily obtained. 
When the drug is not soluble in the organic solvent, it may be encapsulated as a solid 
provided its form is of small size. Nominally, the size of the drug crystals should be at least an 
order of magnitude smaller than the desired microparticle diameter in order to avoid large 
bursts associated with dissolution of larger crystals. Smaller crystals will be more 
homogeneously distributed throughout the organic droplets created in the emulsion. This 
results in a solid-in-oil-in-water emulsion (S/O/W) and may be used with any hydrophilic 
drug.  
The most serious challenge with encapsulating hydrophilic materials is loss of drug to the 
external aqueous phase during the formation of the microparticles. Along with the loss of 
drug to the external phase, the remaining material may migrate to the surface of the droplet 
before hardening. To minimize these problems, the organic droplets should be hardened into 
microparticles as quickly as possible following their formation. The method typically involves 
the use of a viscous organic solution of polymer and drug and a large secondary volume of 
water that essentially extracts the organic solvent into the external aqueous phase 
immediately, thus leaving only the microparticle with encapsulated drug. The highly viscous 
dispersed phase serves two purposes. First, the volume of volatile organic solvent is at a 
minimum, facilitating its quick removal from the droplet. Second, highly viscous material will 
make the migration of the solid drug particles/crystals to the surface of the droplet more 
difficult, resulting in a more homogenous distribution of drug within the microparticle. As an 
alternative to S/O/W emulsions, hydrophilic drugs may be encapsulated in a polymer matrix 
using a multiple water-in-oil-in-water (W/O/W) or oil-in-oil (O/O) emulsions.  
Cisplatin, slightly soluble in water (1 mg/mL),  has been encapsulated in PLGA 
microparticles by a number of research groups (239). Particle size ranges have varied between 
1 and 300 µm with high encapsulation efficiencies (> 90%). However, depending on the type 
of emulsion used, a large burst was often observed in the in vitro release profiles. Release 
times, in vitro, vary between a few days to months depending on the diameter of the 
microparticles and the molecular weight of the polymer used. 
Microparticles prepared from PLGA using a S/O/W emulsion contained 5–15% 5 fluoro-
uracile (5-FU) showed high efficiency and drug loadings with a desirable release profile with 
little to no burst and relatively constant release. Duane T. Birnbaum et all., have prepared 5-
FU microparticles from high and low molecular weight PLGAs as well as a mixture of 
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molecular weights. A S/O/W emulsion was used in conjunction with a highly viscous organic 
phase and an in-liquid drying process. The resulting microparticles were 50–60 µm in 
diameter with encapsulation efficiencies as high as 75% and drug loadings as high as 25%. 
Release profiles in buffered saline from PLGA microparticles showed an initial slow and 
sustained release with no burst and lasts three or more weeks, depending on the molecular 
weight of the PLGA samples used, with higher molecular weight polymers yielding 
formulations with longer controlled-release duration. After the polymer degradation reaches a 
critical phase, the remaining drug is quickly released over a period of about 1 week. Thus the 
release is controlled by both diffusion and polymer hydrolysis rates, resulting in a biphasic 
release profile. The time lag between the slower release phase and the faster release phase can 
be controlled by using different molecular weight PLGA or a blend of PLGA polymers with 
differing molecular weights. Because higher molecular weight PLGA will hydrolyze at a 
slower rate, the initial slow-release phase will last longer when using higher molecular weight 
PLGA, either alone or in a blend. The release profile can be made monophasic by including 
low molecular weight PLGA and hydrophilic polyethylene glycol (PEG) in the formulation. 
LHRH has been encapsulated in PLGA microparticles using a W/O/W emulsion (240). 
Microparticles prepared using a W/O/W emulsion containing 75:25 PLAGA (mol wt: 14,000) 
and 5% LHRH released in vitro for several weeks (>4) with no initial burst of hormone. That 
a water-soluble drug could be efficiently entrapped in a PLGA microparticle and display no 
initial burst using the W/O/W method is somewhat unusual and very encouraging for 
researchers in the field. For example, numerous research groups have used the W/O/W 
method to encapsulated various proteins (e.g., BSA) and the in vitro release typically displays 
a moderate to large burst. That LHRH has both high encapsulation efficiency and no initial 
burst has been attributed to the formation of a micelle-like structure between the PLGA chains 
and the drug (241). The release of the hormone is then strictly regulated by polymer 
degradation rather than diffusion. 
Hydrophobic drugs are typically much easier to encapsulate because they are often highly 
soluble in the volatile organic solvents used in the formulations and thus lack the 
thermodynamic drive to partition to the external aqueous phase. Encapsulation efficiencies 
greater than 90% are typical, with little manipulation of formulation parameters. Challenges 
arise only when the solubility of the drug is low in the desired dispersed-phase solvent. In 
these cases, drug loadings may have to be limited to the maximum concentration obtained in 
the dispersed phase. Alternatively, it may be possible to use a cosolvent system (e.g., 
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dichloromethane and methanol) where the second component is used to increase the 
concentration of drug in the dispersed phase. Hydrophobic drugs often present less of a 
challenge to formulate in slowly degradable microparticle systems, relative to hydrophilic 
drugs, as they are often soluble in the organic solvents used, but are insoluble in water. Many 
hydrophobicdrugs that have been encapsulated in biodegradable microparticles include (242). 
For example taxol has been successively encapsulated in PLGA microparticles with high 
efficiency (> 90%) (242, 243, 244). The maximum amount of drug encapsulated in the 
microparticles typically depends on its solubility in the organic solvent used in the 
formulation. Taxol is now a common anticancer agent used against a wide variety of solid 
tumors including breast and ovarian cancers. It is insoluble in water and has a limited 
solubility in ethanol. Taxol has been encapsulated in PLGA microparticles of varying LA/GA 
ratios using very simple O/W emulsions (244). The authors used dichloromethane as the 
solvent for both PLGA (mol wt: 10,000) and taxol. A 4% gelatin solution was used as the 
continuous phase with simple mechanical mixing. An encapsulation efficiency of 98% from 
microparticles with an average diameter of 30 µm was achieved using 75:25 PLGA with no 
additional additives. The in vitro release displayed a slow-sustained release of taxol with no 
initial burst. In fact, the release was so slow that isopropyl myristate was added to change the 
microparticle matrix to allow the formation of channels that would allow for faster diffusion 
of taxol from the microparticle. These results are not unexpected considering the hydrophobic 
nature of the drug and the immiscible nature of the solvents used for both phases of the 
emulsion. Thermodynamically, taxol must remain solvated in the dichloromethane until 
which time the solvent is completely removed and, thus, the drug is homogeneously 
encapsulated in the newly formed microparticle. Because the release of taxol from PLGA 
microparticles is typically quite slow, the most significant obstacle in formulating these 
microparticles is obtaining a sustained release of therapeutic levels of drug. Thus, additives 
such as isopropyl myristate, sucrose, and the use of PLGAs of varying molecular weight and 
hydrolytic degradation rates have been investigated as a means of accelerating the release of 
taxol (244, 245). 
This biodegradable polymer can be successfully used as controlled delivery systems for many 
type of drugs and for different route of administration. These systems could provide sustained 
release of macromolecules ranging from a few days to several months, which avoid the daily 
multiple administration. Furthermore, encapsulation in polymer matrix also protects labile 
molecules from the degradation by enzymes. The application of these controlled delivery 
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systems result in numerous products in the market. These products all base on polyester 
PLGA due to the favorable regulatory status of the polymer.  
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3. Aim of the Work 
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During the last three decades, therapeutic systems based on polymers, both natural and 
synthetic, have shown to be effective in controlling rate or time of drug release, in enhancing 
drug targeting specificity while lowering systemic drug toxicity, and providing protection for 
pharmaceuticals against degradation.  
An important consideration in the treatment of pulmonary infections is the fact that the MTB 
and MAC have the capability of surviving intra-cellulary in the host macrophages for long 
periods of time (246). Therefore, the ability of the antibacterial agent to eradicate the 
microrganisms within the macrophage is of key importance.  
However, most of the anti-mycobacteria drugs presently in use fail to penetrate macrophages. 
For this reason, many researchers are considering the use of appropriately engineered delivery 
systems for these drugs, in order to make them therapeutically effective. It is well known that 
micro-encapsulation technology can be used to accomplish sustained release of antibiotics, 
when they are formulated in larger sizes than 50 µm, or to target drug delivery systems to 
specific cells (i.e., macrophages), when antibiotics are formulated in smaller sizes <10µm. 
RFP, one of the first choice drugs for TB and MOTT infections, requires high-doses and 
prolonged treatment (4–6 months). Moreover, it is known that resistance develops (247), 
while several side effects have been reported in long term therapy (248). For these reasons, 
several types of novel drug delivery devices have been proposed and characterized for RFP 
administration, in order to maximize the therapeutic and minimize the toxic and side effects 
for this drug (249, 250, 251). Polymeric drug carriers are included between the various types 
of drug delivery systems proposed. Although experience with synthetic polymers is extensive 
and encouraging, more recently the trend has been to shift towards natural polymers as 
alginate and chitosan. Main advantages of these polymers are their low cost and compatibility 
with the encapsulation of a wide range of drugs, with minimal use of organic solvents. 
Furthermore, bio-adhesion, stability, safety and approval for human use by the US FDA are 
additional advantages.  
The purpose of the present study was to develop particulate carriers for the delivery of RFP in 
the treatment of MTB and MAC pulmonary infections, and evaluate their suitability to be 
delivered to the lungs by nebulization therapy. To this purpose we prepared and characterised 
RFP-loaded chitosan, PLGA or a mixtures of the two polymers (Chitosan coated PLGA 
particles) microspheres.  
RFP-loaded chitosan microparticles have never been prepared before.  
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Biodegradable microparticles composed of poly(lactide-co-glycolide) (PLGA) can be 
considered as a well established drug delivery system, having high potential to serve as 
carriers for drugs as well as vaccines (252, 253). One such application is the alveolar delivery 
of RFP. PLGA has been used before for the preparation of RFP loaded microspheres, and 
several studies have been carried out mainly for evaluation of the formulation parameters that 
influence the release kinetics of RFP from particles. Furthermore, it has been established that 
these particles can reach alveolar macrophages after aerosol delivery and enhance the 
therapeutic effect of RFP in vivo (254). In addition, while RFP-loaded PLGA microspheres 
have been prepared and evaluated in vivo previously, no relevant pre-formulation studies 
involving their behaviour during nebulization, have been carried out. 
In the present study we compared chitosan, PLGA or mixtures of the two polymers (Chitosam 
coated PLGA particles) for the preparation of particulate RFP delivery systems that may be 
administered to the lungs by nebulization. For this, the three types of particles were prepared 
and their ability to encapsulate RFP was evaluated. After this, using the same nebulization 
device we evaluated the nebulization ability of the different types of microparticles prepared. 
During this study we also compared properties of freshly prepared and freeze-dried 
microspheres in order to evaluate freeze-dried formulations for rapid re-hydration just before 
nebulization. 
During this work we studied the influence of several formulation parameters on microparticle 
size distribution, encapsulation efficiency (E%) and nebulization efficiency (NE%). 
Since association of RFP with particles is a prerequisite for achieving high RFP 
concentrations in alveolar macrophages, the most important characteristic for these particles is 
their ability to retain the drug during the nebulization process, which was also evaluated. 
Furthermore, a morphological assessment of the particles by Scanning Electron Microscopy 
was carried out. Toxicity of the prepared microspheres was also evaluated by using A549 
alveolar epithelial cells 
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In this chapter we describe the preparatione and characterization of RFP as a potential 
effective approach to pulmonary MTB and MAC infection therapy. RFP loaded chitosan 
microspheres were prepared by using precipitation and precipitation chemical-cross-linking 
methods. Both of them are simple methods that do not require complex apparatus, special 
precautions and the use of organic solvents. Additionally, fewer purification steps are 
necessary than in other described methods. Precipitation chemical cross-linking involves the 
precipitation of the polymer followed by crosslinking. Precipitation can be done in both cases 
by sodium sulphate followed by chemical crosslinking using glutaraldehyde (220).  
In particular, the influence of several parameters (chitosan concentration, and cross-linking 
agents) on microparticle size distribution, (E%), nebulization efficiency (NE%) and leakage 
upon nebulization have been studied. Toxicity of chitosan microspheres were evaluated by 
using A549 alveolar epithelial cells. 
4.1. Materials and Methods 
4.1.1. Material 
Medium molecular weight chitosan with a deacetilation grade of about 87%, rifampicin 
(RFP), sodium sulphate, glutaraldehyde (GA) and acetic acid were provide by Sigma Aldrich 
(Germany). Lyophilised bovine submaxillary glands mucin (type I-S) was purchased from 
Sigma Aldrich. 
A549 cells (Passage 31) was a kind gift from Dr. Ben Forbes (School of Pharmacy, Kings 
College, London) and were cultured in Ham’s F12-K medium Biochrom (Berlin, Germany), 
supplemented with 10% fetal bovine serum (Gibco BRL Life Technology, Grand Island, NY, 
USA), 100µg/ml penicillin G (Sigma Aldrich), and 100 µg/ml streptomycin sulphate (Sigma 
Aldrich) at 37°C in a humidified 95% air and 5% CO2 environment. Cultures (monolayers in 
tissue culture flasks, 75 cm2) were fed with fresh medium every 48 h. 
All other reagents were of the highest grade commercially available. Water was always used 
in demineralised form. 
4.1.2. Preparation of RFP-Loaded Chitosan Microspheres 
RFP was dissolved in a acqueous solution of acetic acid (2% v/v), chitosan at different 
concentration were also added. A solution of sodium sulphate (20% w/v) was puted in, drop-
wise, during stirring with ultraturrax® at 500 rpm and ultrasonication in a bath-type 
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ultrasonifier, for 30 minutes. After addition of sodium sulphate, in some formulations, a 
solution of GA (25% w/w) was also added to evaluate the influence of cross-linking agents. 
Microspheres were purified by centrifugation for 15 minutes at 3000 rpm. The obtained 
sediment then was suspended in water. These two purification steps were repeated twice. All 
purified particles then were lyophilized.  
4.1.3. Characterization of RFP-Loaded Chitosan Microspheres 
4.1.3.1. Particle Sizing  
Microspheres were analysed for their size and polydispersity index on Nano-ZS (Nanoseries, 
Malvern Instruments), based on photon correlation spectroscopy, at a scattering angle of 90° 
and temperature of 25°C. Each measurement was the result of 12 runs. Measurements were 
carried out for both fresh and freeze-dried samples.  
Before counting, the samples were diluted with a 0.05% (w/v) tween 80 water solution in 
order to prevent precipitation during the measurements. Results are the means of triplicate 
experiments. 
4.1.3.2. Surface Charge (Zeta-Potential) 
The surface charge of the microspheres was determined with Nano-ZS (Nanoseries, Malvern 
Instruments). The measurements were carried out in an aqueous solution of KCl 0,1N. 
Immediately before the determinations, microspheres were diluted with KCl solution. The 
measured values were corrected to a standard reference at temperature of 20°. Results are the 
means of triplicate experiments. 
4.1.3.3. Particles Morphology 
The Optical Microscopy (OM) (Zeiss Axioplan 2), was used for the determination of the 
shape of RFP loaded chitosan microspheres. A small drop of microspheres suspension was 
placed on a clean glass slide. The slide containing RFP loaded chitosan microspheres was 
mounted on the stage of the microscope and observed.  
For scanning electron microscopy (SEM) several drops of the microsphere suspension were 
placed on an aluminum stub having previously been coated with adhesive. The samples were 
evaporated at ambient temperature until completely dried, leaving only a thin layer of 
particles on the stub. All samples were sputter coated with gold-palladium (Polaron 5200, VG 
Microtech,West Sussex, UK) for 90 seconds (2.2 kV; 20 mA; 150–200A°) under an argon 
atmosphere. The SEM (Model 6300, JEOL, Peabody, NY) was operated using an acceleration 
voltage of 10 kV. 
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4.1.3.4. Measurement of Loading Efficiency of RFP in Chitosan Microspheres 
A series of RFP solutions of known concentrations in acetonitrile were prepared, and 
absorbances were measured in order to generate a standard curve.  
The rifampicin content of each lot of microspheres was determined by first extracting the RFP 
and quantifying the amount of drug spectrophotometrically. 
The drug encapsulation efficiency was calculated as the percentage of drug entrapped in 
microspheres compared with the initial amount of drug recovered in unpurified samples. The 
concentration of rifampicin contained in each sample was determined by measuring the 
absorbance on a spectrophotometer at 485 nm. 
4.1.3.5 Nebulization Studies of Microspheres 
A compressor nebuliser system (Medel Aerofamily, Italy) was used in the study. A volume of 
3 ml of sample was used for the nebulization. The aerosols containing RFP-loaded chitosan 
microspheres were collected in water using a modified 3 stages glass impinger similar to 
those in Figure 4.1. The impinger device was utilized with the collecting flask containing 3 ml 
of water to which the aerosol was introduced through a calibrated glass tube and critical 
orifice delivering the jet of aerosol 5 mm above the bottom of the flask. 
After aerosolization (10 minutes), and taking into account the dilution (after measuring the 
exact volume of dispersion collected), the RFP contained in the impinger were assayed in 
order to evaluate the effect of nebulization on drug leakage from microspheres and the total 
amount of formulation nebulised into the apparatus. The Nebulization Efficiency (NE%) of 
microsphere formulations is defined as the total output of drug collected on the impinger as a 
percentage of the total drug submitted to nebulization.  
 
NE% = (Aerosolised drug /Total drug placed in nebuliser) x 100 
 
Because nebulization can lead to drug leakage, it is important to also determine the 
nebulization efficiency of the encapsulated drug (NEED%). This parameter is defined as the 
percentage of aerosolised drug that remains encapsulated after nebulization. A portion of 
nebulised sample was purified by centrifugation and the amount of drug in the sample before 
and after centrifugation was assayed. 
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Fig.4.1: Collecting Nebulised Formulations of Microspheres for Evaluating Effects Upon 
Nebulization 
4.1.4. Release/Stability Studies 
In vitro release of RFP from chitosan microspheres was determined using, as the release 
media, phosphate buffer (pH 7.4) and acetate buffer (pH 4.4) in order to simulate the 
condition in the lungs, and SGF (pH 1.2), in order to evaluate the stability of chitosan 
microspheres in acidic medium. Freeze-dried formulations were suspended in 500 ml of the 
dissolution medium, and the amount of microspheres was varied in order to kept constant the 
amount of drug (25 mg). The experiments were carried out at 37 ± 0.3°C at a rotation speed of 
100 ± 2 rpm. A measure of 1 ml samples were withdrawn at appropriate time intervals and 
centrifuged at 10000 rpm. Supernatants were diluted suitably with acetonitrile and absorbance 
of the resulting solution was measured at 485 nm in a UV spectrophotometer. The residue 
(after centrifugation) was redispersed in 1 ml of the fresh dissolution medium and replaced 
back into the dissolution apparatus. The cumulative amount of RFP was obtained from the 
calibration curve of RFP in acetonitrile. The stock standard solution of RFP (2 mg/ml) was 
prepared by dissolving the drug in acetonitrile and storing at 4°C. A standard calibration 
curve was built up by using standard solutions prepared by dilution of the stock standard 
solution with acetonitrile.  
4.1.5. Mucoadhesive Studies 
4.1.5.1. Adsorption of Mucin on Chitosan Microspheres 
Bradford colorimetric method (255) was used to determine the free mucin concentration in 
order to assess the amount of mucin adsorbed on the microspheres and its effect on the 
assessment of mucoadhesive behavior of chitosan microspheres. 
Standard calibration curves were prepared from 2 mL of mucin standard solutions (0.25, 0.5, 
0.75, and 1 mg/2 mL). After adding Bradford reagent, the samples were incubated at 37°C for 
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20 minutes and then, the absorbance of the solution was recorded at 595 nm in a UV 
spectrophotometer. Triplicate samples were run.  
Mucin aqueous solution with different concentrations (0.025, 0.1, and 0.5 mg/mL) were 
prepared. Freeze-dried chitosan microspheres (20 mg) were dispersed in the above mucin 
solutions, vortexed, and shaken at room temperature. Then, the dispersions were centrifuged 
at 4000 rpm for 10 minutes, and the supernatant was used for the measurement of the free 
mucin content. The mucin content was calculated from the standard calibration curve. 
4.1.6. Cell Culture 
The human A549 alveolar epithelial cell line (Passage 31) shows similar features as type II 
alveolar epithelial cells. The cells were grown as monolayers in 35 mm tissue culture dishes 
incubated in 100% humidity and 5% CO2 at 37°C. HAM’S medium containing 365 mg/L L-
glutamine, supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL 
penicillin, and 100 µg/mL streptomycin was used as the growth media. The cells that form the 
monolayers were harvested with trypsin (0.25%) centrifuged at low speed (1600 g, 4 min), 
resuspended in fresh medium and plated at a concentration of 2 x 105 cells/dish. The cells 
were grown to confluence on tissue culture dishes for 3 to 4 days.  
4.1.6.1. MTT Assay 
For dose-dependent studies, cells were treated with RFP alone and RFP-loaded chitosan 
microspheres at different concentration in RFP. The effect of RFP in microspheres on the 
viability of cells was determined by [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] MTT assay (256). The dye is reduced in mitochondria by succinic dehydrogenase to 
an insoluble violet formazan product. A549 cells (105 cells/well) were cultured on 24-well 
plates with 500 µl of medium for 24 h, with and without the tested compounds. Then 50 µl of 
MTT (5 mg/ml in PBS) were added to each well and after 2 h, formazan crystals were 
dissolved in DMSO. Absorbance at 580 nm was measured with a spectrophotometer. On the 
basis of this assay IC50 values were obtained in three independent experiments for each 
formulation. In all assays three different concentrations were used. In order to evaluate 
changes in viability caused by the tested compounds, living cells as well as those in early and 
late stages of apoptosis and necrosis were counted. All other methods were also carried out 
after 24 h incubation. The data in this study were expressed as mean ± S.D of at list three 
experiments. 
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4.1.7. Statistical Analyses 
All experiments were repeated at least three times. Results are expressed as means ± standard 
deviation. A difference between means was considered significant if the “p” value was less 
than or equal to 0.05. 
4.2. Result and Discussion 
4.2.1. Preparation of RFP-Loaded Chitosan Microspheres 
The primary goal of this study was to prepare microsphere formulations that could be used to 
target the delivery of effective doses of RFP to macrophages after aerosol therapy.  
Precipitation and precipitation chemical-cross-linking methods are rapid and simple 
techniques for producing RFP-loaded microspheres with small size and good reproducibility 
from batch to batch. This production process is based on the solubility behaviour of chitosan, 
which is poorly soluble in water. Addition of an acid improves its solubility as a result of 
protonation of amino groups. Chitosan solubility is also affected by other anions present in 
the solution. In the presence of phosphate, polyphosphate and sulphate ions, chitosan shows a 
decreased solubility. For this reason, sodium sulphate was chosen for microsphere 
formulations, since sulphate leads to a poorly soluble chitosan derivative, whereby 
microsphere formulation become possible.  
Composition of RFP-loaded chitosan microspheres is reported in table 4.1. 
 
Table 4.1: Chitosan Microspheres Composition 
 
 RFP CTS Sodium Sulphate (20% w/w) 
Acetic 
Acid 
GA 25% 
(w/w) 
Form.Ø 2mg/ml 0.20% 0.16 ml 2% - 
Form.1 2mg/ml 0.25% 0.2 ml 2% - 
Form.2 2mg/ml 0.50% 0.4 ml 2% - 
Form.3 2mg/ml 0.75% 0.6 ml 2% - 
Form.Ø G 2mg/ml 0.20% 0.16 ml 2% + 
Form.4 2mg/ml 0.25% 0.2 ml 2% + 
Form.5 2mg/ml 0.50% 0.4 ml 2% + 
Form.6 2mg/ml 0.75% 0.6 ml 2% + 
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4.2.2. Size and Morphological Characteristics of Microspheres 
RFP-loaded chitosan microspheres were obtained in the size ranging from 1 to 3 µm. All 
formulations were monodispersed as shown by the polidispersity index that was always in the 
range 0.16-0.29 (table 4.2). all particles in this study were also freeze-dried and tha influence 
of this procedure on microspheres properties was evaluatedin order to design a freeze-dried 
formulation capable of being rapidly hydrated nad nebulized for the delivery of RFP to lung 
macrophages. PCS analyses showed that lyophilization did not affect microsphere size (data 
not shown). 
As can be seen from the table, microsphere size increased as chitosan concentration and, 
therefore, solution viscosity increased. As expected cross-linked microspheres were smaller 
than the corresponding uncross-linked particles: these differences in size indicate that cross-
linked microspheres were more compact in structure because of the cross-linkage.  
 
Table 4.2: Particle Size and Zeta Potential of Chitosan Microspheres 
 
Formulation Particle Size (nm ± SD) P.I ± SD Zeta Potential (mV ± SD) 
Form.Ø NM NM NM 
Form.1 2310 ± 106 0.160 ± 0.027 +32.5 ± 0.4 
Form.2 2470 ± 50.99 0.238 ± 0.011 +34.7 ± 0.1 
Form.3 2710 ± 77.88 0.252 ± 0.013 +37.0 ± 0.2 
Form.Ø G NM NM NM 
Form.4 1470 ± 20.13 0.210 ± 0.089 +23.7 ± 0.6 
Form.5 1730 ± 26.30 0.290 ± 0.018 +21.9 ± 0.2 
Form.6 2190 ± 47.60 0.243 ± 0.092 +15.6 ± 0.2 
 
Microsphere formation and particle morphology were studied with optical microscopy and 
SEM. Optical micrographs showed round particles, in a range of size that confirmed PCS 
measurements. SEM micrographs showed that uncross-linked microspheres were spherical 
and more regular in shape than the cross-linked ones. As can be seen from figure 4.2, cross-
linking with GA gave particles different in shape and with a rough surface. 
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 a b 
Figure 4.2: Sem Micrographs of Uncross-Linked Particles (a) and Cross-Linked 
Particles (b) 
4.2.3. Surface Charge 
Zeta potential has a substantial influence on the stability of suspensions, the interaction of 
microspheres with charged drugs, and also on the adhesion of drug delivery systems onto 
biological surfaces. Consequently, investigation of the zeta potential is an important part of 
microsphere characterization. Phosphate buffer influenced measurement of zeta potential, due 
to the effect of the counterions on the positively charged chitosan microspheres. For this 
reason a solution of KCl 0.1N was used for charge surface measurements. 
Chitosan microspheres were positively charged (Table 4.2), although sulphate ions were used 
as precipitant. This indicates that only a part of the amino groups are neutralized during 
microsphere formation. A different behaviour could be observed between uncross-linked and 
cross-linked microspheres zeta potential. In fact, while the zeta potential of the uncross-linked 
particles slightly increased as chitosan concentration increased, the contrary was obtained 
with the cross-linked particles formulations. Moreover, the zeta potential of these last 
formulations was smaller than the corresponding uncross-linked formulations 1-3 as a 
consequence of reduction of amino groups because of interaction with GA. 
4.2.4. Entrapment Efficiency (E%) 
Figure 4.4 shows the encapsulation efficiency (E%) of the prepared microspheres. In the 
present work, the influence of chitosan concentration and cross-linking agent on the RFP 
entrapment in microspheres was evaluated. The highest E% was found in formulations 
prepared with the lowest amount of chitosan, that are Form. Ø and Form. ØG obtained 
without and with GA respectively. Chitosan concentration affected considerably the E: in 
particular the loading capacity increased as the chitosan concentration decreased. This is 
because the increase in chitosan concentration led to increased solution viscosity that 
drecreased the loading capacity of the microspheres as a consequence of the reduced drug 
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solubilization. Part of the drug was not dissolved during preparation process and/or it was 
probably lose from the microspheres during the washing steps.  
GA does not affect significantly the E% that was very similar to that obtained with the 
corresponding uncross-linked particles.  
Encapsulation efficiency were estimated before and after freeze-drying. As can be seen in 
figure 4.4, freeze-drying does not cause any leakage of the encapsulated drug from the 
chitosan microspheres. Additionally, it should be stated that the powder produced by the 
freeze-drying was very easily re-hydrated by one-step addition of the appropriate volume of 
water, a fact that is important for the desired use intended for the RFP loaded microparticles. 
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Figure 4.4: Encapsulation Efficiency (E%) Before and After Freeze-Drying 
4.2.5. Nebulization Studies of Chitosan Microspheres 
Nebulization studies were carried out in order to evaluate the stability and the suitability of 
chitosan particles for pulmonary/nasal administration. For this reason different analyses were 
performed on nebulized samples. All these studies were performed by using both freshly 
prepared and freeze-dried microspheres. It must be pointed that only nebulized particles 
trapped in water was assayed, while the material deposited on the wall of the impinger was 
not included in the analysis since it might have dried and disrupted causing drug leakage. 
After nebulization, particles size was measured in order to evaluate the effect of this process 
on mean particle size and size distribution, table 4.3.  
Uncross-linked particles, especially Form. 1, showed a decrease in mean particle size. This 
result could be due to a low stability of the uncross-linked formulations that probably suffered 
the nebulization energy that caused particle breaking. Cross-linked particles, as can be seen in 
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the table, did not vary significantly in size after the nebulization process thus confirming their 
higher stability. All samples were still monodispersed as shown by their low P.I. value. 
 
Table 4.3: Particle Size of Chitosan Microspheres Before and After Nebulization Process 
Formulation 
Particle Size (nm 
± SD) 
Before Nebulization 
P.I ± SD Particle Size 
(nm ± SD) 
After nebulization 
P.I ± SD 
Form. Ø NM NM NM NM 
Form. 1 2310 ± 106 0.160 ± 0.027 1697 ± 54,62 0,234 ± 0,046 
Form. 2 2470 ± 50.99 0.238 ± 0.011 2120 ± 72,11 0,232 ± 0,028 
Form. 3 2710 ± 77.88 0.252 ± 0.013 2440 ± 47,44 0,291 ± 0,017 
Form. ØG NM NM NM NM 
Form. 4 1470 ± 20.13 0.210 ± 0.089 1770 ± 18,16 0,213 ± 0,076 
Form. 5 1730 ± 26.30 0.290 ± 0.018 1693 ± 92,37 0,297 ± 0,022 
Form. 6 2190 ± 47.60 0.243 ± 0.092 2480 ± 44,22 0,364 ± 0,054 
 
Using the nebulization device described in the experimental section, we evaluated the 
nebulization ability of the different types of prepared microparticles. Since association of RFP 
with particles is a prerequisite for achieving high RFP concentration in alveolar macrophages, 
the most important characteristic for these particles is their ability to retain the drug during the 
nebulization process, which was also evaluated.  
As can be seen in figure 4.5, the percentage of RFP collected in nebulized microparticle 
samples (NE%) ranged from 34.35 to 53.0% although the different microparticle formulations 
showed different nebulization ability for RFP loaded particles. In fact, significant differences 
were measured for NE% among the different nebulized chitosan microparticles. Indeed, as the 
chitosan concentration in the particles decreased (which results in a decrease of the particle 
dispersion viscosity), their NE% increased. A negative effect of viscosity on NE% was 
demonstrated previously during nebulization of liposomes (257). 
However, the cross-linked chitosan particles (with GA) always demonstrated slightly higher 
NE% compared to the non-cross-linked ones.  
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Figure 4.5: Nebulization Efficiency (NE%) Before and After Freeze-Drying 
 
The retention of the drug in the nebulized particles (NEED%) is maybe the most important 
parameter when a formulation is studied for nebulization delivery. This parameter, in fact, 
gives important information on the capability of the produced microparticles to retain the 
encapsulated drug in high amount during the nebulization procedure. Cross-linking chitosan 
particles with GA definitely resulted in an increased stability during nebulization as it can be 
concluded by comparing the NEED% values measured for the corresponding uncross-linked 
chitosan formulations (figure 4.6). In fact, as we said before, GA is able to stabilize chitosan 
microspheres by immobilizing also the drug encapsulated. NEED% was also affected by the 
chitosan concentration: it increased as the chitosan concentration decreased.  
Freeze-dried microspheres were re-suspended in water and also in this case all the parameters 
were evaluated. As can be seen in figures 4.5 and 4.6, NE% and NEED% remained almost the 
same after freeze-drying, and these results suggested that the stability of chitosan 
microspheres was not affected after liophilization and redispersion process. 
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Figure 4.6: Nebulization Efficiency of The Encapsulated Drug (NEED%) Before and 
After Freeze-Drying 
4.2.6. Release/Stability Studies 
Release studies were carried out by using three different release media. Phosphate buffer at 
pH 7.4 and acetic acid buffer at pH 4.4 were used in order to evaluate the influence of the pH 
inside phagosome and lysosome on RFP release from chitosan microspheres. In Figure 4.7 
and 4.8, RFP release profiles from RFP-loaded chitosan microspheres at pH 4.4 and 7.4 buffer 
solutions respectively, are shown. 
As can be seen from the figures, an initial burst effect was observed from all chitosan 
microparticles (between 19 and 30% of loaded RFP). After this initial burst, all studied 
microspheres released RFP at a lower rate. RFP release from the was pH dependent (faster 
release at pH 4.4 than at pH 7,4). This is attributed to the higher solubility of the polymer at 
lower pH. In fact, as proposed earlier (258), chitosan microspheres can also provide pH-
responsive release profile by swelling in acidic environment of the gastric fluid. When 
comparing the release profiles from cross-linked (with GA) and uncross-linked chitosan 
microspheres, we see that at pH 7.40 the release of RIF is substantially decreased in the cross-
linked particles. It has been proposed before that GA addition in chitosan particles can be 
used as a method to modulate release kinetics of drugs, as demonstrated for theophylline 
(259). However, the difference between the release kinetics of RFP from the two types of 
chitosan particles is more or less diminished (or is a lot smaller) at pH 4.40, possibly due to 
the rapid swelling and increased solubility of this polymer at low pH, which results in a very 
fast release of particle- loaded RFP from all chitosan microspheres during the first 8 hours of 
incubation.  
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Figure 4.9: Release Studies pH 1.2 
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Stability of chitosan microspheres at pH 1.2 was also evaluated by studying the drug release. 
As can be seen in figure 4.9, the release in this acidic medium is even faster than that obtained 
at pH 4.4. Obviously, this is related to the highly acidic release medium that caused the higher 
ionization of the D-glucosamine residues with a resulting faster and higher swelling degree, 
and a very fast release of the drug. As it is evident from the graph, a strong burst effect was 
found with from 22.3 to 41.5% of RFP released in the first 2 hrs of the experiments. However, 
also in this case the crosslinking with GA led a decrease of the drug release rate.  
4.2.7. Mucoadhesive Studies 
Advantages of mucoadhesive properties of particles for inhalation therapy are a cause of 
argue among scientists. In fact, considering the meaning of mucoadhesion and taking into 
account the lung mucociliary clearance it could seems a disadvantage. However, it is well 
known that the mucociliary clearance is more important in the upper airways while particulate 
adhesion to the mucus layer of the lungs can activate macrophage activity. Finally, it is also 
important to underline that chitosan exerts a transient inhibitory effect on mucociliary 
clearance of the bioadhesive formulations due to its surface charge, molecular contact and 
flexibility, and this is a further advantage for the delivery of RFP to the lungs and in particular 
to macrophages where the MTB and MAC are able to replicate. 
Since a strong interaction exists between mucin and chitosan, mucin should be spontaneously 
adsorbed to the surface of the chitosan microspheres. For this reason, the mucoadhesive 
behaviour of chitosan microspheres was assessed by suspending chitosan microspheres in 
different amounts of mucin aqueous solutions at room temperature. As can be seen in figure 
4.10 the amount of mucin adsorbed increased by increasing mucin concentration. These 
results confirmed that chitosan microspheres have the ability to adsorb mucin. No statistically 
difference could be observed in the capability to adsorb mucin between uncross- and cross-
linked microspheres (Figure 4.10) although a higher mean value of adsorbed mucin was 
always obtained from the uncross-linked microspheres. The adsorption of mucin to chitosan is 
expected to be dominated by the electrostatic attraction between positively charged chitosan 
and negatively charged mucin (the negative charge of mucin is due to the ionization of sialic 
acid). Therefore, surface charge of chitosan microspheres represented by zeta potential would 
influenced the amount absorbed. For all the batches the amount of adsorbed mucin decreased 
with decreasing in zeta potential. 
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Figure 4.10: Mucoadhesive Studies of Chitosan Microspheres  
 
4.2.8. Viability Studies with A549 Cells 
The cytotoxic effects of RFP against A549 cells were examined by MTT assay. In the 
experiments, the cytotoxicity was evaluated by varying the concentration of free and 
microsphere-encapsulated RFP. This study was carried out only on Formulation 1 (uncross-
linked) and Formulation 4 (cross-linked), which had been prepared with 0.25% of chitosan. 
Cytotoxicity was observed to be RFP concentration-dependent for all the tested samples 
(Figure 4.11). The highest cytotoxic effects were found for free RFP, which even in the 
lowest concentration (0.1%) showed only a 55% cell viability that further decreased to 12% 
when the free drug was used in the highest concentration (0.5%). These results show the high 
toxicity of RFP that can cause side effects also when it is nebulized directly into the lung, 
where is the site of infection. The viability assay also showed that RFP toxicity can be 
reduced by encapsulating the drug in chitosan microspheres. Cell viability was generally not 
affected by chitosan concentration, in fact empty particles showed always the best results in 
term of viability. As can be seen in figure 4.11 the presence of GA decreased the viability of 
cells probably because same cross-linking agent was in the particles also after the purification 
steps. 
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Figure 4.11: Viability Studies whit A549 Cells  
 
4.3. Conclusion 
Chitosan is a versatile polymer whose applications range from weight supplement in the 
market to a drug carrier in formulation research. Cross-linking agents such as GA has been 
used for preparation of microspheres. The particle size of chitosan microspheres can be 
modified approximately for the pulmonary delivery of drugs. The entrapment efficiency of 
drugs in the chitosan microspheres is dependent upon the chitosan concentration. Also the 
release of drug from chitosan microspheres is dependent upon the concentration of chitosan, 
but also upon drug content and density of cross linking. 
The potential bioadhesiveness of these microspheres are important properties required for the 
treatment of MTB and MAC infections. Taking together the good bioacceptibility of chitosan, 
its positive charge that seems to be very advantageous for bioadhesion to the normally 
negatively charged biological membranes, the suitable release profile for RFP, the possibility 
to modulate RFP release from chitosan microspheres by adding cross-linking agent (GA), the 
above presented microspheres may represent useful tools for the delivery of antitubercular 
drug by aerosol therapy. 
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Spray drying is a well-known process, which is used to produce dry powders, granules, or 
agglomerates from drug-recipient solutions and suspensions. In the present study, RFP 
entrapped chitosan microspheres, were prepared by using spray-drying method. Particles were 
characterized for particle size, drug encapsulation efficiency, and in vitro suitability for 
aerosol delivery.  
In particular, preparation and characterization of rifampicin loaded chitosan microspheres as a 
potential effective approach to pulmonary MTB and MAC infections therapy was studied; the 
influence of several parameters (chitosan concentration, and cross-linking agents) on 
microparticle size distribution, entrapment efficiency (E%), nebulization efficiency (NE%) 
and leakage upon nebulization have been studied.  
5.1. Materials and Methods 
5.1.1. Material 
Medium molecular weight chitosan with a deacetilation grade of about 87%, rifampicin 
(RFP), GA and acetic acid were provide by Sigma Aldrich Chemie (Germany). Lyophilised 
bovine submaxillary glands mucin (type I-S) was purchase from Sigma Aldrich. 
All other reagents were of the highest grade commercially available. Water was always used 
in demineralised form. 
5.1.2. Preparation of RFP-Loaded Chitosan Microspheres 
RFP-loaded chitosan microspheres, obtained by spray drying method, were prepared by 
dissolving different amounts of chitosan in an aqueous solution of 2% acetic acid (v/v). RFP 
with and without cross-linking agent (GA 4%, GA) were added to the chitosan solution, under 
stirring with Ultraturrax® at 500 rpm, and the mixtures were spray-dried from a 0.5 nozzle at 
a feed rate of 6ml/min (BUCHI Mini Spray Dryer B-290). The inlet and outlet temperature 
were maintained at 150°C and 95°C, respectively. The spray dried product was collected by a 
cyclone separator. 
Microspheres were purified after redispersion in wather by centrifugation for 15 minutes at 
3000 rpm in order to evaluate the encapsulation efficiency. The obtained sediment then was 
suspended in water. These two purification steps were repeated twice. 
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5.1.3. Characterization of RFP-Loaded Chitosan Microspheres 
5.1.3.1. Particle Sizing and Morphology 
The microspheres were analysed for their size and polydispersity index on Dynamic Light 
Scattering (N4 Plus Beckman Coulter), based on photon correlation spectroscopy, at a 
scattering angle of 90° and temperature of 25°, using a mathematically constrained regulation 
(SDP analysis CONTIN program) to overcome the limitation of unimodal analysis for 
complex distribution. Each measurement was the results of 4 runs. 
Before counting, the samples were dissolved with a 0.05% (w/v) tween 80 water solution in 
order to prevent precipitation during the measurements. Results are the means of triplicate 
experiments. 
5.1.3.2. Surface Charge (Zeta-Potential) 
The surface charge of the microspheres was determined with Zetasizer Nano ZS, Malvern 
Instruments. The measurements were carried out in an aqueous solution of KCl 0,1N. 
Immediately before the determinations microspheres were diluted with KCl solution. The 
measured values were corrected to a standard reference at temperature of 20°. Results are the 
means of triplicate experiments. 
5.1.3.3. Particle Morphology 
The surface morphology of microparticles was observed by both scanning electron 
microscopy (SEM) and optical microscopy (OM). The optical microscopy (Zeiss Axioplan 2) 
was used for the determination of the shape of RFP loaded chitosan microspheres. A small 
drop of microspheres suspension was placed on a clean glass slide. The slide containing RFP 
loaded chitosan microspheres was mounted on the stage of the microscope and observed.  
The morphological characteristic features of RFP loaded chitosan microspheres were studied 
using a scanning electron microscope. Spray-dried microspheres were mounted on metal stubs 
and then coated with a 150Å layer of gold. Photographs were taken using Zeiss-DSM962 
Scanning Electron Microscope. 
5.1.3.4. Analisi Frattale 
 
5.1.3.5. Measurement of Loading Efficiency of RFP in Chitosan Microspheres 
A series of RFP solutions of known concentrations in acetonitril were prepared, and 
absorbances were measured in order to generate a standard curve. The RFP content of each lot 
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of microspheres was determined by first extracting the RFP and quantifying the amount of 
drug spectrophotometrically.  
The drug encapsulation efficiency was calculated as the percentage of drug entrapped in 
microspheres compared with the initial amount of drug recovered in unpurified samples. The 
concentration of rifampin contained in each sample was determined by measuring the 
absorbance on a spectrophotometer at 485 nm. 
5.1.3.6 Nebulization of Microspheres 
RFP-loaded chitosan microspheres aerosols were generated using an efficient high-output 
continuous-flow Markos Mefar MB2 nebulizer, driven by a Nebula compressor (Markos 
Mefar) operated at 7l/min. A volume of 3 ml of sample was used for the nebulization. The 
aerosols containing RFP-loaded chitosan microspheres were collected in a water solution 
using a modified 3 stages glass impinger. The impinger device was used with the collecting 
flask containing 3 ml of water to which the aerosol was introduced through a calibrated glass 
tube and critical orifice delivering the jet of aerosol 5 mm above the bottom of the flask. 
After aerosolization (10 minutes), the impinger contents were assayed in order to evaluate the 
effect of nebulization on drug leakage of microspheres. The secondary aim of this experiment 
was also to determine the total amount of formulation nebulised into the apparatus. The 
nebulization efficiency (N.E%) of microsphere formulations is defined as the total output of 
drug collected on the impinger as a percentage of the total submitted to nebulization.  
 
NE% = (Aerosolised drug /Total drug placed in nebuliser) x 100 
 
Because nebulization can lead to drug leakage, it is important to also determine the 
nebulization efficiency of the encapsulated drug (N.E.E.D%). This parameter is defined as the 
percentage of aerosolised drug that remains encapsulated after nebulization. A portion of 
nebulised sample was purified by centrifugation and the amount of drug in the sample after 
and before centrifugation was assayed. 
5.1.4. Release Studies/Stability Studies 
In vitro release of RFP from chitosan microspheres was determined using as the release 
media, phosphate buffer pH 7.4 in order to simulate some of the conditions in the lungs, and 
pH 1.2 in order to evaluate the stability of chitosan microspheres in acidic medium. Freeze-
dried formulations were suspended in 500 ml of the dissolution medium, and the amount of 
microspheres was varied in order to kept constant the amount of drug (25 mg). The 
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experiments were carried out at 37 ± 0.3°C at a rotation speed of 100 ± 2 rpm. A measure of 1 
ml samples were withdrawn at appropriate time intervals and centrifuged at 10000 rpm. 
Supernatants were diluted suitably with acetonitrile and absorbance of the resulting solution 
was measured at 485 nm. The residue (after centrifugation) was redispersed in 1 ml of the 
fresh dissolution medium and replaced back into the dissolution apparatus. The cumulative 
amount of RFP was obtained from the calibration curves of RFP in acetonitrile. The stock 
standard solution of RFP (2 mg/ml) was prepared by dissolving the drug in acetonitrile and 
storing at 4°C. A standard calibration curve was built up by using standard solutions prepared 
by dilution of the stock standard solution with acetonitrile.  
5.1.5. Mucoadhesive Studies 
5.1.5.1. Adsorption of Mucin on Chitosan Microspheres 
Standard calibration curves were prepared from 2 mL of mucin standard solutions (0.25, 0.5, 
0.75, and 1 mg/2 mL) and then, the absorbance of the solutions was recorded at 500 nm in a 
UV spectrophotometer. Triplicate samples were run.  
Mucin aqueous solution with different concentrations (0.025, 0.05, 0.1, 0.2, and 0.5 mg/mL) 
were prepared. Chitosan microspheres (20 mg) prepared by spray-drying method were 
dispersed in the above mucin solutions, vortexed, and shaken at room temperature. Then, the 
dispersions were centrifuged at 4000 rpm for 2 minutes, and the supernatant was used for the 
measurement of the free mucin content. The mucin content was calculated from the standard 
calibration curve. 
5.1.6. Statistical Analyses 
All experiments were repeated at least three times. Results are expressed as means ± standard 
deviation. A difference between means was considered significant if the p value was less than 
or equal to 0.05. 
5.2. Result And Discussion 
5.2.1. Preparation of RFP-Loaded Chitosan Microspheres 
In order to find the best microsphere formulations for the delivery of effective doses of RFP 
to macrophages after aerosol therapy, we also prepared and characterized chitosan 
microspheres of by using an alternative preparation method that is spray drying.  
Also in this case uncross- and crosslinked (GA) microparticles were prepared and the 
influence of different parameters was studied.. 
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Composition of RFP-loaded chitosan microspheres, prepared by the spray drying method, is 
reported in table 5.1. 
 
Table 5.1: Spray-Dried Chitosan Microspheres Composition  
 
 
 
 
 
 
 
 
 
 
5.2.2. Size and Morphological Characteristics of Microspheres 
Spray-dried chitosan microparticles showed a mean particle size ranging from 0.6 to 1.5 µm. 
As can be seen in table 5.2, microsphere size and polidispersity increased as chitosan 
concentration and, therefore, solution viscosity increased. This result was probably due to the 
effect of the solution viscosity on the droplet size during the atomization step. In general, the 
mean size of droplets formed by atomization is proportional to liquid viscosity and surface 
tension and it indirectly affects the spray-dried powder size, being an important processing 
variable.  
The cross-linking degree controls chitosan microspheres properties and Table 5.2 shows a 
little increase in the mean size of cross-linked mcirospheres.  
Morphology of microparticles was verified with optical microscopy (OM) and SEM. OM 
images showed round particles, with size in the same range found by PCS analysis. (Figure 
5.2a and 5.2b). SEM images showed that microspheres obtained by the spray-drying method 
were of good morphological characteristics, spherical shape and smooth surface. Figures 5.3a 
and 5.3b show a sample of both cross-linked and uncross-linked chitosan microspheres (batch 
A and E respectively). No morphological difference was highlighted for these two different 
microspheres. Therefore results seem to indicate that GA does not affect the morphological 
characteristics of cross-linked microspheres obtained by the spray-drying method. 
 
 RFP CTS Acetic Acid GA 4 % (w/w) 
Form.A 2mg/ml 0.25% 2% + 
Form.B 2mg/ml 0.50% 2% + 
Form.C 2mg/ml 0.75% 2% + 
Form.D 2mg/ml 1% 2% + 
Form.E 2mg/ml 0.25% 2% - 
Form.F 2mg/ml 0.50% 2% - 
Form.G 2mg/ml 0.75% 2% - 
Form.H 2mg/ml 1% 2% - 
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Table 5.2: Particle Size and Zeta Potential of Spry-Dried Chitosan Microspheres 
Formulation 
Particle Size (nm ± 
SD) 
P.I ± SD Zeta Potential (mV ± 
SD) 
Form. A 577.0 ± 68.6 0.854 ± 0.020 +23.7 ± 0.6 
Form. B 914.3 ± 59.9 0.689 ±0.028 +21.9 ± 0.2 
Form. C 1003.2 ± 24.7 0.717 ± 0.020 +15.6 ± 0.2 
Form. D 1181.0 ± 121.6 0.593 ± 0.029 + 15.4 ± 0.1 
Form. E 661.5 ± 13.7 0.728 ± 0.030 +32.5 ± 0.4 
Form. F 1070.5 ± 103.1 0.215 ±0.027 +34.7 ± 0.1 
Form. G 1202.1 ± 27.7 0.840 ± 0.016 +37.0 ± 0.2 
Form. H 1306.0 ± 41.1 0.926 ± 0.028 +38.07 ± 0.05 
 
Moreover, SEM micrographs confirmed the high heterogenicity of particle size distribution, 
which is a consequence of the preparation method. In fact it is well known that using spray-
drying method it is not possible to control size distribution of the particles. 
   
 a b 
Figure 5.1: Optical Micrographs of Cross-Linked Spray-Dried Microspheres (a) and 
Uncross-Linked Spry-Dried Microspheres (b) 
    
 a b 
Figure 5.2: SEM Micrographs of Cross-Linked Spray-Dried Microspheres (a) and 
Uncross-Linked Spry-Dried Microspheres (b) 
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5.2.3. Surface Charge 
Investigation of zeta potential is an important part of microsphere characterization. This 
parameter was investigated by using a solution of KCl 0.1N since phosphate buffer could not 
be used due to the effect of the counterions on the positively charged chitosan microspheres.  
All chitosan formulations were positively charged as can be seen in table 5.2.  
It was found that the cross-linking with GA led to a decrease of the zeta potential of chitosan 
microspheres as a consequence of diminution of free amino groups in chitosan structure. In 
fact, GA reacts with chitosan through the formation of covalent bonds mainly with the amino 
groups of the polysaccharide.  
5.2.4. Entrapment Efficiency (E%) 
Figure 5.4 shows the encapsulation efficiency (E%) of the prepared microspheres. All 
formulations showed very good E%, always ranging between 50% for uncross-linked 
particles and 80% for cross-linked microspheres. E% of spray-dried microspheres was 
affected by chitosan concentration: E% decreased as chitosan concentration increased. The 
increase in chitosan concentration led to highly viscous solutions that reduced drug solubility 
and therefore the loading capacity. 
The influence of the cross-linking agent on the RFP entrapment in chitosan microspheres was 
also evaluated.  
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Figure 5.3: Entrapment Efficiency (E%) of Spray-Dried Microspheres 
 
As can be seen in figure 5.4, cross-linked particles (Formulation A-D) showed the best E% 
because of their stability during atomization and washing steps. 
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5.2.5. Nebulization Studies of Chitosan Microspheres 
Nebulization studies were carried out in vitro in order to evaluate stability and suitability of 
chitosan microparticles for the pulmonary administration. All these studies were performed by 
dispersing the spray-dried microspheres in water. RFP-microsphere aerosols, generated using 
a continuous-flow nebulizer, were collected in a buffer solution in a three stage glass impinger 
and analysed for the study of nebulization efficiency (NE%) and nebulization efficiency of the 
encapsulated drug (NEED%) that is the percentage of aerosolized drug that remains 
encapsulated after nebulization. These studies are of particular importance to have 
information of the capability of the microspheres to be aerosolized and also to retain the 
entrapped drug during the process. To this purpose, the study was carried out only on the 
microspheres that were able to reach the aqueous compartment of the impinger. The 
microparticles deposited on the impinger walls were not included in the study since their 
likely dehydration could have caused drug leakage.  
During this study, we evaluated the influence of the nebulization process on the particle size. 
In general, nebulized microspheres showed and increased mean size and a reduced 
polydispersity index, as can be seen in table 5.3. It is important to underline that formulation 
H, the most chitosan concentrated uncross-linked formulation, showed the highest increase of 
particle size. The mean size increase observed in the nebulized particles is probably due to 
chitosan swelling after their dispersion in water, before the nebulization study. This is 
particular true for the uncross-linked particles where the swelling process is faster.  
 
Table 5.3:Particle Size of Spray-Dried Microspheres Before and After Nebulization 
Process 
Formulation 
Particle Size (nm 
± SD) 
Before nebulization 
P.I ± SD 
Particle Size 
(nm ± SD)  
After nebulization 
P.I ± SD 
Form. A 577.0 ± 68.6 0.854 ± 0.020 671,3 ± 1,3 0,187 ± 0,013 
Form. B 914.3 ± 59.9 0.689 ±0.028 883,4 ± 2,7 0,457 ± 0,030 
Form. C 1003.2 ± 24.7 0.717 ± 0.020 1164,1 ± 12,1 0,439 ± 0,041 
Form. D 1181.0 ± 121.6 0.593 ± 0.029 1567,5 ± 1,7 0,505 ± 0,021 
Form. E 661.5 ± 13.7 0.728 ± 0.030 780,8 ± 13,2 0,155 ± 0,035 
Form. F 1070.5 ± 103.1 0.215 ±0.027 1177,2 ± 8,1 0,626 ± 0,022 
Form. G 1202.1 ± 27.7 0.840 ± 0.016 1277,8 ± 5,4 0,407 ± 0,012 
Form. H 1306.0 ± 41.1 0.926 ± 0.028 2058,3 ± 1,2 0,606 ± 0,040 
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As can be seen in Figure 5.4, cross-linked formulations A-D showed better NE% than 
uncrossed linked formulations: almost 80% of rifampicin was recovered after nebulization 
from formulations A-C. On the contrary, NE% was quite low for the uncross-linked 
formulations E-H, thus confirming their stability is lower than that of the corresponding GA 
containing formulations.  
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Figure 5.4: Nebulization Efficiency (NE%) of Spray-Dryed Microspheres 
 
Since nebulization can lead to drug leakage, it is also important to evaluate how much of the 
aerosolized drug is still encapsulated after the nebulization (NEED%). Best results in terms of 
NEED% were obtained from the cross-linked formulations A-D that were able to retain up to 
70% of the encapsulated drug. NEED values were affected by chitosan concentration: they 
decreased as chitosan concentration increased. Once again, uncross-linked formulations E-H 
showed very poor nebulization properties since NEED values ranged from 5 to 20%. Results 
obtained in this analysis seem to point out that the most important factor affecting NEED is 
polymer cross-linkage, as can be seen by the comparison of NEED values from formulations 
obtained using the same amount of chitosan in Figure 5.5. Cross-linkage contributes to 
improve chitosan microsphere stability by immobilizing the encapsulated drug  
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Figure 5.5: Nebulization Efficiency of the Encapsulated Drug (NEED%) of Spray-Dryed 
Microspheres 
5.2.6. Release/Stability Studies 
Release studies were carried out by using two different mediums, phosphate buffer at pH 7.4 
and SGF at pH 1.2, in order to evaluate the effect of pH on RFP release from chitosan 
microspheres. In Figure 5.6 and 5.7, RFP release profiles from RFP-loaded chitosan 
microspheres in both release mediums are shown. Reported values are the arithmetical mean 
of at list three measurements. Only dissolution profiles from formulations A and E (the most 
stable and with) the slowest amount of chitosan) are shown in the figure in order to better 
evaluate the influence of the cross-linking agent, withoth any other variable.  
Rifampicin release from the chitosan microspheres is pH dependent: it is faster at pH 1.2 than 
at pH 7.4. This is the consequence of the higher solubility of chitosan at lower pH, where the 
D-glucosamine residues are ionized resulting in an extensive polymer swelling and faster drug 
release. Moreover, rifampicin solubility is pH dependent: it increases as the pH increases. In 
fact, as proposed earlier, chitosan microspheres can also provide pH-responsive release profile 
by swelling in acidic environment of the gastric fluid. When comparing the drug release 
profiles from cross-linked and un-cross-linked chitosan microspheres, a substantial decrease 
of the release rate is obtained from the cross-linked microparticles at pH 7.4. 
As can be seen from the graphs, in both cases there is a significant burst effect, which is more 
important for formulation E that in only 0.5 hours released 24 (pH 7.4) and 43% (pH 1.2) of 
the encapsulated drug while formulation A in the same period released 16 and 25% at pH 7.4 
and pH 1.2 respectively. 
Obtained results show that cross-linkage with GA can delay drug release as a consequence of 
the higher stability of the hydrogel network. In fact, in both media the cross-linked 
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formulation A is more capable of controlling the drug release than formulation E that released 
the 90% of the drug in 48 hours at pH 1.2. 
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 Figure 5.6: Release Studies pH 7.4 Figure 5.7: Release Studies pH 1.2 
 
5.2.7. Mucoadhesive Studies 
Aerosol inhalation therapy via the respiratory tract is desirable for delivering drugs since it 
has the following advantages over other routes: lung surface area is extremely large and 
mucosal permeation of drug is comparatively easy because the vascular system is well 
developed and the walls of alveoli are extremely thin. Finally the intra-cellular or extra-
cellular activity of drug-metabolizing enzymes is relatively low.  
Since a strong interaction exists between mucin and chitosan, mucin should be spontaneously 
adsorbed to the surface of the chitosan microspheres. The mucoadhesive behaviour of 
chitosan microspheres was assessed by their suspension in different amounts of mucin in 
aqueous solutions at room temperature. As can be seen in Figure 5.8 the amount of adsorbed 
mucin increased with increasing mucin concentration. These results confirm that chitosan 
microspheres have the ability to adsorb mucin. The amount of mucin adsorbed was affected 
by the presence of the cross-linking agent. In fact cross-linked microspheres interacted with a 
lower amount of mucin, probably because of the cross-linkage and the reduced positive 
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charge since amino groups are partially neutralized by GA. In fact, for all the batches the 
amount of mucin adsorbed decreased as the zeta potential of particles decreased. 
Microspheres with the highest zeta potential (uncross-linked formulations E-H) had the 
largest amount of adsorbed mucin. 
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Figure 5.8: Mucoadhesive Studies of Spry-Dried Chitosan Microspheres  
 
5.3. Conclusions 
Results obtained during this work showed that the spray drying method is a rapid and simple 
technique for producing RFP loaded microspheres in good yields, high E% and good 
reproducibility from batch to batch. In particular, microspheres prepared by this method 
showed to possess suitable properties for aerosol delivery. In fact comparison of results with 
those obtained with the precipitation method pointed out that microparticles prepared by the 
spray-drying process showed higher stability during nebulization. 
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Poly(lactide-co-glycolide) (PLGA) is a the most used polymer owing to its 
biocompatibility/biodegradability and PLGA microparticles have been successfully employed 
as ATD-carriers.  
PLGA microspheres can be able to achieve slow release rates of RFP in alveolar macrophages 
that are essential to treat MTB and MAC infections, since these bacillus are facultative 
intracellular parasites in alveolar macrophages and microspheres can penetrate into the 
infected macrophages by phagocytosis.  
RFP loaded PLGA microspheres were prepared by using solvent evaporation method that 
need the use of organic solvents (CHCl3).  
In this chapter we describe the preparation and characterization of rifampicin loaded PLGA 
microspheres as a potential effective approach to pulmonary MTB and MAC infections 
therapy. In particular microparticle size distribution, entrapment efficiency (E%), nebulization 
efficiency (NE%) and leakage upon nebulization have been studied. The toxicity of PLGA 
microspheres were evaluated by using A549 alveolar epithelial cells. 
6.1. Materials and Methods 
6.1.1. Material 
PLGA (75:25), rifampicin (RFP), polyvinil alcool (PVA) were provide by Sigma Aldrich 
Chemie (Germany). Lyophilised bovine submaxillary glands mucin (type I-S) was purchase 
from Sigma Aldrich. 
The A549 epithelial alveolar cell line (passage 31) was a kind gift from Dr. Ben Forbes 
(School of Pharmacy, Kings College, London) and these cells were cultured in Ham’s F12-K 
medium (Sigma Aldrich), supplemented with 10% fetal bovine serum (Gibco BRL Life 
Technology, Grand Island, NY, USA), 100 µg/ml penicillin G (Sigma Aldrich), and 100 
µg/ml streptomycin sulphate (Sigma Aldrich) at 37°C in a humidified 95% air and 5% CO2 
environment. Cultures (monolayers in tissue culture flasks, 75 cm2) were fed with fresh 
medium every 48 h. 
All other reagents were of the highest grade commercially available. Water was always used 
in demineralised form. 
6.1.2. Preparation of PLGA Microspheres 
PLGA microspheres were prepared by an O/W solvent evaporation method adapted from 
Prieto et al. (1994). For the preparation of RFP-loaded PLGA microspheres, two different 
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methods were chosen. In the first PLGA and RFP were dissolved in the organic phase and in 
the second the drug was dissolved in the aqueous phase. Briefly twenty milligram of PLGA 
was dissolved in 1 ml of dichloromethane (DCM). This was dispersed in 4 ml of an aqueous 
phase of 4% PVA. The resultant emulsion was homogenised for 10 min with an Ultraturax® 
homogeniser at 800 rpm. Subsequent evaporation of the DCM was carried out with 
mechanical stirring over night at room temperature. Microparticles were collected by 
centrifugation and washed by dispersion in water with subsequent centrifugation, this step 
was repeated three times. Microspheres were than freeze dried. 
6.1.3. Characterization of RFP-Loaded PLGA Microspheres 
6.1.3.1. Particle Sizing and Morphology 
The microspheres were analysed for their size and polydispersity index on Zetasizer Nano ZS, 
Malvern instruments, based on photon correlation spectroscopy, at a scattering angle of 90° 
and temperature of 25°. Each measurement was the results of 12 run.  
Measurements were carried out both for fresh and freeze-dried samples. Before counting, the 
samples were diluted with a 0.05% (w/v) tween 80 water solution in order to prevent 
precipitation during the measurements. Results were the means of triplicate experiments. 
6.1.3.2. Surface Charge (Zeta-Potential) 
The surface charge of the microspheres was determined with Zetasizer Nano ZS, Malvern 
instruments. The measurements were carried out in an aqueous solution of KCl 0.1N. 
Immediately before the determinations microspheres were diluted with KCl solution. The 
measured values were corrected to a standard reference at temperature of 20°. Results are the 
means of triplicate experiments. 
6.1.3.3. Particle Morphology 
In preparation for scanning electron microscopy (SEM) several drops of the microsphere 
suspension were placed on an aluminum stub having previously been coated with adhesive. 
The samples were evaporated at room temperature until completely dried, leaving only a thin 
layer of particles on the stub. All samples were sputter coated with gold-palladium (Polaron 
5200,VG Microtech,West Sussex, UK) for 90 seconds (2.2 kV; 20 mA; 150–200A°) under an 
argon atmosphere. The SEM (Model 6300, JEOL, Peabody, NY) was operated using an 
acceleration voltage of 10 kV. 
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6.1.3.4. Measurement of Loading Efficiency of RFP in PLGA Microspheres 
A series of rifampin solutions of known concentrations in acetonitril were prepared, and 
absorbances were measured in order to generate a calibration curve. The rifampin content of 
each lot of microspheres was determined by first extracting the rifampin and quantifying the 
amount of drug spectrophotometrically.  
The drug encapsulation efficiency (E%) was calculated as the percentage of drug entrapped in 
microspheres compared with the initial amount of drug recovered in unpurified samples. The 
concentration of rifampin contained in each sample was determined by measuring the 
absorbance on a spectrophotometer at 485 nm. 
6.1.3.5. Nebulization of Microspheres 
A compressor nebuliser system (Medel Aerofamily, Italy) was used in this study. 3 ml of 
purified sample were used for the nebulization studies. The aerosols containing RFP-loaded 
chitosan microspheres were collected in a water solution using a modified 3 stages glass 
impinger. The impinger device was used with the collecting flask containing 3 ml of water to 
which the aerosol was introduced through a calibrated glass tube and critical orifice delivering 
the jet of aerosol 5mm above the bottom of the flask. 
After aerosolization (10 minutes), the impinger contents were assayed in order to evaluate the 
effect of nebulization on stability of microspheres and the drug leakage during this process. 
After the experiment was also determined the total amount of formulation nebulised into the 
apparatus. The nebulization efficiency (N.E%) of microsphere formulations is defined as the 
total output of drug collected on the impinger as a percentage of the total submitted to 
nebulization.  
 
NE% = (Aerosolised drug /Total drug placed in nebuliser) x 100 
 
Because nebulization can lead to drug leakage, it is important to also determine the 
nebulization efficiency of the encapsulated drug (N.E.E.D%). This parameter is defined as the 
percentage of aerosolised drug that remains encapsulated after nebulization. A portion of 
nebulised sample was purified by centrifugation and the amount of drug in the sample after 
and before centrifugation was assayed after complete extraction of the drug from particles 
with acetonitrile. 
6.1.4. Release Studies/Stability Studies 
In vitro release of RFP from PLGA microspheres was determined using as the release 
mediums, phosphate buffer pH 7.4 and acetate buffer at ph 4.0 in order to simulate the 
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condition in lungs. Freeze-dried formulations were suspended in 500 ml of the dissolution 
medium, the amount of microspheres was varied in order to kept constant the amount of drug 
(25 mg). The experiments were carried out at 37 ± 0.3°C at a rotation speed of 100 ± 2 rpm. A 
measure of 1 ml samples were withdrawn at appropriate time intervals and centrifuged at 
10000 rpm. Supernatants were diluted suitably with acetonitrile and absorbance of the 
resulting solution was measured at 485 nm. The residue (after centrifugation) was redispersed 
in 1 ml of the fresh dissolution medium and replaced back into the dissolution apparatus. The 
cumulative amount of RFP was obtained from the calibration curves of RFP in acetonitrile. 
The stock standard solution of RFP (2 mg/ml) was prepared by dissolving the drug in 
acetonitrile and storing at 4°C. A standard calibration curve was built up by using standard 
solutions prepared by dilution of the stock standard solution with acetonitrile.  
6.1.5. Mucoadhesive Studies 
6.1.5.1. Adsorption of Mucin on PLGA Microspheres 
Bradford colorimetric method was used to determine the free mucin concentration in order to 
assess the amount of mucin adsorbed on the microspheres and its effect on the assessment of 
mucoadhesive behavior of chitosan microspheres. 
Standard calibration curves were prepared from 2 mL of mucin standard solutions (0.1, 0.25, 
0.5, 0.75, and 1 mg/2 mL). After adding Bradford reagent, the samples were incubated at 
37°C for 20 minutes and then, the absorbance of the solution was recorded at 595nm in a UV 
spectrophotometer. Triplicate samples were run. All the samples were determined with the 
same procedure.  
The evaluation of mucoadhesive properties was carried out by preparing mucin aqueous 
solution with different concentrations (0.025, 0.1, and 0.5 mg/mL). PLGA microspheres (20 
mg) were dispersed in the above mucin solutions, vortexed, and shaken at room temperature. 
Then, the dispersions were centrifuged at 4000 rpm for 10 minutes, and the supernatant was 
used for the measurement of the free mucin content. The mucin content was calculated from 
the standard calibration curve. 
6.1.6. Cell Culture 
The human A549 alveolar epithelial cell line shows similar features as type II alveolar 
epithelial cells. The cells were grown as monolayers in 35 mm tissue culture dishes incubated 
in 100% humidity and 5% CO2 at 37°C. HAM’S medium containing 365 mg/L L-glutamine, 
supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, and 100 
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µg/mL streptomycin  was used as the growth media. The cells that form the monolayers were 
harvested with trypsin (0.25%) centrifuged at low speed (1600 g, 4 min), resuspended in fresh 
medium and plated at a concentration of 2 x 105 cells/dish. The cells were grown to 
confluence on tissue culture dishes for 3 to 4 days.  
6.1.6.1. MTT Assay 
For dose-dependent studies, cells were treated with RFP alone and RFP-loaded PLGA 
microspheres at different concentration in RFP. The effect of RFP in microspheres on the 
viability of cells was determined by [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] MTT assay (256). The dye is reduced in mitochondria by succinic dehydrogenase to 
an insoluble violet formazan product. A549 cells (105 cells/well) were cultured on 24-well 
plates with 500 µl of medium for 24 hours, with and without the tested compounds. Then 50 
µl of MTT (5 mg/ml in PBS) were added to each well and after 2 h, formazan crystals were 
dissolved in DMSO. Absorbance at 580 nm was measured with a spectrophotometer. On the 
basis of this assay IC50 values were obtained in three independent experiments for each 
formulation. In all assays three different concentrations were used. In order to evaluate 
changes in viability caused by the tested compounds, living cells as well as those in early and 
late stages of apoptosis and necrosis were counted. All other methods were also carried out 
after 24 h incubation. The data in this study were expressed as mean ± S.D. 
6.1.7. Statistical Analyses 
All experiments were repeated at least three times. Results are expressed as means ± standard 
deviation. A difference between means was considered significant if the p value was less than 
or equal to 0.05. 
6.2. Result and Discussion 
6.2.1. Preparation of RFP-Loaded PLGA Microspheres 
Solvent evaporation method is the most popular technique of preparing PLGA microparticles. 
It involves emulsifying a drug-containing organic polymer solution into a dispersion medium. 
Depending on the state of drug in the polymer solution and the dispersion medium, it can be 
further classified into oil in water (o/w), water in oil (w/o), and water in oil in water (w/o/w) 
double emulsion method. The o/w method was used in this work. For this technique, drug is 
dissolved or dispersed in a solution of the polymer in a water-immiscible and volatile organic 
solvent (DCM). This dispersion is emulsified into an aqueous phase. The organic solvent then 
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diffuses into the aqueous medium and finally evaporates into the air. In the solvent 
evaporation method, poly(vinyl alcohol) (PVA) is widely used as an emulsifier in the external 
aqueous phase and dichloromethane is the most commonly used solvent to dissolve the 
polymer. The o/w emulsion method was varied in our laboratory in order to make particles by 
adding the drug not only in the organic phase but also in the aqueous phase. 
In fact two types of particles were prepared: the first ones were obtained by dissolving RFP in 
the organic phase (1) and the second ones were obtained by dissolving RFP in the aqueous 
phase (2). These different samples were prepared in order to evaluate the influence of drug 
solubility on different parameters (E%, NE% and NEED%) and on particle characteristics. 
Composition of RFP-loaded PLGA microspheres is reported in table 6.1. 
 
Table 6.1: RFP-loaded PLGA Microspheres Composition  
 
 
 
 
 
6.2.2. Size and Morphological Properties of PLGA Microspheres 
RFP-loaded PLGA microspheres were obtained in the size range around 2 µm and good 
polidispersity index as shown in table 6.2. The size distribution of PLGA microspheres was 
evaluated before and after freeze-drying process. Lyophilized microspheres were mixed with 
water, vortexed for few minutes and than measured. No change in average particle size 
appeared after lyophilization and resuspension (data not shown).  
 
Table 6.2: Particle Size and Zeta Potential of PLGA Microspheres 
Formulation 
Particle Size (nm ± 
SD) 
P.I ± SD Zeta Potential (mV ± 
SD) 
PLGA 1 2563 ± 49.32 0.192 ± 0.030 
-4.60 ± 0.2 
PLGA 2 2606 ± 61.10  0.203 ± 0.049 
-4.80 ± 0.1 
 
As can be seen in table 6.2 the addition of the drug in the organic or in the aqueous phase did 
not affect particle size and this is probably because RFP is an amphipatic drug and it can be 
dissolved in both organic and aqueous phases, although it is more lipophilic. 
 RFP PLGA PVA 
Form. 1 2 mg/ml 2 mg/ml 4% 
Form. 2 2 mg/ml 2 mg/ml 4% 
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PLGA microparticles size is normally affected by the presence of an emulsifier. In this case 
PVA was used to prevent aggregation of the emulsion droplets and polymer sticking during 
stirring. 4% of PVA was able to stabilize particles also during their storage. This is confirmed 
by the polydispersity index tha was very low because aggregation did not occur and particles 
mantained a narrow distribution, as confirmed also by SEM study. 
When working with microparticulate systems, it is often helpful to visualize particle shapes 
and surface characteristics in order to correlate other properties such as surface area and size 
distribution. RFP-loaded PLGA microspheres prepared using the solvent evaporation method 
were spherical in shape with a very smooth surface, as shown in Figures 6.1a and 1b. The 
loading of the antimicrobial agent did not cause any significant change in morphology.  
SEM micrographs confirmed the narrow distribution of particles size found by PCS 
measurement, for each batch. As can be seen, no difference in particle morphology was found 
as a consequence of the preparation method.  
 
   
 a b 
Figure 6.1: SEM Micrographs of PLGA Microspheres Obtained by Adding the Drug in 
the Aqueosus Phase (a) or in the Organic Phase (b).  
6.2.3. Surface Charge 
Microparticle formulations were characterized also in term of zeta potential because, as well 
known, it can influence particle stability as well as particle mucoadhesion. In theory, more 
pronounced zeta potential values, being positive or negative, tend to stabilize particle 
suspension. The electrostatic repulsion between particles with the same electric charge 
prevents the aggregation of the spheres. The PLGA particles made by the solvent evaporation 
method were negatively charged  as can be seen in table 6.2 and, hence, were poorly 
mucoadhesive. At a neutral pH value the mucus layer is an anionic polyelectrolyte. 
Mucoadhesion is promoted by a positive zeta potential value and, thus, the presence of the 
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positively charged groups on the particles could lead to electrical charge interactions between 
the mucus and the particles. PLGA negatively charged microspheres were stable and dit not 
aggregate as confirmed also by SEM investigation, but this surface property make them 
poorly mucoadhesive. 
6.2.4. Entrapment Efficiency (E%) 
Encapsulation efficiency (E%) is an important index to evaluate drug-loaded microspheres as 
it is more economical when high encapsulation efficiency can be obtained. An O/W emulsion 
technique is mostly used for the encapsulation of drugs. One objective of this study was 
therefore to investigate the influence of drug solubility on the RFP entrapment in PLGA 
microspheres. 
Figure 6.2 shows E% of the prepared microspheres. As can be seen, no significant difference 
was found between formulation 1 and 2. However, formulation 1, wich was obtained by 
adding the drug in the organic phase, showed a higher E% (72%) than formulation 2 (E% = 
65%). This small difference could be related to the higher affinity of RFP for the organic 
phase. 
Encapsulation efficiency was measured before and after freeze-drying in order to evaluate the 
effect of this process on the drug retention. As can be seen in figure 6.2, freeze-drying did not 
cause any leakage of the drug encapsulated in chitosan microspheres. It was important to 
evaluate the effect of the freeze-drying process on this parameter because the aim of this 
study, like for chitosan particles, was to obtain a stable product, in powder form, able to be 
rapidly rehydrated just before its use. 
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Figure 6.2: Encapsulation Efficiency (E%) of PLGA Microspheres 
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6.2.5. Nebulization Studies of PLGA Microspheres 
Nebulization studies were carried out in order to evaluate the stability and the suitability of 
PLGA particles for pulmonary/nasal administration. All these studies were performed by 
using both freshly prepared and freeze-dried microspheres. Different analyses were performed 
on the nebulized samples. As for chitosan microspheres, only the sample trapped in water was 
assayed, while the material deposited on the impinger walls was not included. 
Size of particles was evaluated after the nebulization process and, as can be seen in table 6.3, 
there was an important decrease of mean particle size and also a significant increase of 
polidispersity index. The decrease on mean size during nebulization can be explained taking 
into account that during this process small particles can be nebulized easily. Nebulization 
proved that PLGA microspheres, prepared during this work, were multidimensional as it is 
shown by the high P.I. value. In fact, three different microsphere populations were obtained in 
the three different impinger stages. The increase in P.I. could also be related to the fact that 
size analysis was carried out by DLLS, whose sensitivity is not really appropriate for particles 
in the micron range. 
Table 6.3:Particle Size of Spray-Dried Microspheres Before and After Nebulization 
Process 
Formulation 
Particle Size (nm 
± SD) 
Before nebulization 
P.I ± SD 
Particle Size 
(nm ± SD) 
After nebulization 
P.I ± SD 
PLGA 1 2563 ± 49.32 0.192 ± 0.030 1073 ± 35.11 0.778 ± 0.053 
PLGA 2 2606 ± 61.10  0.203 ± 0.049 1166 ± 32.61 0.857 ± 0.013 
 
For all microsphere formulations nebulization efficiency and drug leakage after nebulization 
were evaluated. Both these parameters depend on the stability of particles.  
As can be seen in figure 6.3 all formulations showed a good nebulization efficiency (NE%) 
from 72% for PLGA 1 obtained by adding RFP in the organic phase, to 65% for PLGA 2 
obtained by adding RFP in the aqueous phase. During the nebulization process, part of the 
drug can be lost as a consequence of different processes. In fact, some particles, which are too 
big, can not be nebulized while others can be disrupted during the process. The little lower 
NE% of PLGA 2 formulation is probably connected to the preparation method. In fact, by 
adding RFP in the aqueous phase it is possible to have some drug on the particle surface, from 
which can be lose easily during the nebulization process. 
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Figure 6.3: Nebulization Efficiency (NE%) of PLGA Microspheres 
 
This behaviour was also confirmed by studing the drug leakage after nebulization. PLGA 1 
showed the highest medium NEED% value, (figure 6.4), although no significant difference 
can be observed between the two formulations. Freeze-dried microspheres were rapidly re-
hydrated and also in this case all the parameters (NE% and NEED%) were evaluated. As can 
be seen in figures 6.3 and 6.4, NE% and NEED% remained almost the same after freeze-
drying and these results suggest that the stability of PLGA microspheres was not affected by 
the liophilization and redispersion process.  
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Figure 6.4: Nebulization Efficiency of the Encapsulated Drug (NEED%) of PLGA 
Microspheres 
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6.2.6. Release/Stability Studies 
In vitro drug release profile reveals fundamental information on the structure (e.g., porosity) 
and behavior of a formulation on a molecular level, as well as possible interactions between 
drug and polymer, and their influence on the rate and mechanism of drug release and model 
release data. 
Release studies were carried out by using two different release medium, phosphate buffer at 
pH 7.4 and acetic acid buffer at pH 4.4, in order to have the same pH values present inside 
phagosome and lysosome and to evaluate the effect of pH on RFP release from PLGA 
microspheres. In Figure 6.5 and 6.6, RFP release profiles from PLGA microspheres at pH 7.4 
and 4.4 buffer solutions respectively are shown.  
The release profiles were very similar in the two different release media. Normally, the 
release medium pH is able to affect the drug release pattern from PLGA-based microparticles. 
In this case it was found the same behaviour at pH 7.4 and at pH 4.4 during the 72 hours 
experiments. 
The main reason that can explain this behaviour is correlated to the transition temperature 
(Tg) of the polymer. In fact it is well know that PLGA polymer Tg is commonly above the 
physiological temperature of 37 °C, which gives it enough mechanical strength to be 
fabricated into delivery devices. Tg increases with increase of lactic acid content in 
copolymer, because the extra methyl group on the lactic acid moiety increases the rigidity of 
the polymer chain because of the steric hindrance. Moreover, as polymer molecular weight 
increases a reduced polymer chain mobility is obtained. In fact, increase in the polymer chain 
length enhances the intra- and interpolymer chain interactions such as chain entanglement and 
packing, which decrease the polymer chain mobility and consequently increase Tg. On the 
other hand, it has been found that the release of RFP or other drugs from PLGA particles is 
influenced by PLGA monomer composition (lactid acid/glycolic acid). 
As seen from the results in both cases the PLGA microparticles are able to control  RFP 
release rate, and the initial burst effect demonstrated for this type of particles (12% of RFP 
loaded in particles) is significantly low if compared to that obtained from chitosan particles. 
Moreover, after this initial burst, PLGA microspheres released RFP at a lower rate (chapter 
4). 
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 Figure 6.5: Release Studies pH 7.4 Figure 6.6: Release Studies pH 4.4 
 
6.2.7. Mucoadhesive Studies 
The mucoadhesive behaviour of PLGA microspheres was studied at room temperature by 
suspension of particles in different mucin aqueous solutions at different concentrations. As 
can be seen in figure 6.7, the amount of mucin adsorbed is very low but it increased with the 
increasing of mucin concentration. These results confirm that PLGA microspheres are not 
able to adsorb mucin. This is in agreement with zeta potential data. In fact it is well known 
that interaction between particles and mucus are prevalently electrostatic attractions but both 
mucus and PLGA particles are negatively charged and thus they can not interact.  
Therefore, the slow amount of mucin adsorbed is only due to the physical entanglement of 
mucin strands. And the flexible polymer chains (diffusion theory). 
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Figure 6.7: Mucoadhesive Properties of PLGA Microspheres 
 
6.2.8. Viability Studies with A549 Cells 
The cytotoxic effects of RFP against A549 cells were examined by MTT assay. In the 
experiments, the cytotoxicity was evaluated by varying the concentration of RFP and RFP 
entrapped in PLGA microspheres. Cytotoxicity was observed to be concentration-dependent 
for free RFP and for the formulations. Higher cytotoxic effects were found for free RFP. In 
fact, as can be seen in figure 6.8, also with the lowest concentration of RFP the viability is 
very low. This means that the free drug can cause side effects when it is nebulized directly 
into the lung, where the infection is. Even using the smallest concentration, the free RFP is 
able to kill the lung cells (epithelial cells similar to A549 cells). As written before, the target 
of this work was especially the macrophages where mycobacteria are able to survive and 
replicate. As can be seen from the figure, encapsulation of RFP in the PLGA microspheres led 
to a decrease of the cytotoxicity, which was quite close to that of the free drug only at the 
lowest tested RFP concentration . 
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Figure 6.8: Viability Studies with A549 Cells 
6.3. Conclusions 
Results obtained during this study have shown that PLGA microspheres can lead RFP in very 
good yields. These particles showed good properties and stability during nebulization. 
Summarizing the results of this study, we may conclude that with the exception of their 
substantially lower mucoadhesive properties, the PLGA polymer is better that chitosan, for 
the formation of particles that could deliver RFP to alveolar macrophages by nebulisation. 
Thereby, an interesting addition to the properties of RIF-loaded PLGA particles would be to 
improve their mucoadhesive properties through surface modification.  
  
 
 
 
 
100 
  
 
 
 
 
101 
7. Rifampicin Loaded PLGA Coated 
Chitosan Microspheres Prepared by WSD 
Method 
 
 
7. RFP Loaded PLGA Coated Chitosan Microspheres Obtained by WSD Method 
 
 
 
 
102 
Biodegradable microparticles made of poly(lactide-co-glycolide) (PLGA) are well-established 
delivery systems for therapeutics, and have a high potential for peptide, protein and other 
therapeutic substances. Thanks to its established safety record, PLGA continues to be 
prevalently used in the field, although the stability of certain entrapped drug like protein, 
remains a major issue. Nevertheless, one of the typical deficiencies of aliphatic polyesters 
such as PLGA is their lack of suitable functional groups for an efficient and stable deposition 
or conjugation of bioactive agents under mild conditions. Surfaces coated with functional 
polymers or bearing bioactive ligands represent an increasingly desirable feature for drug 
delivery through microparticulate or nanoparticulate systems besides controlled release and 
protection of bioactive agents from premature clearance and degradation. Various approaches 
have been proposed to functionalize the surface of biodegradable microparticles and 
nanoparticles. The negatively charged surface of PLGA microparticles has been 
functionalized by the electrostatic binding of cationic surfactants such as 
cetyltrimethylammonium bromide (260). An alternative to cationic surfactants is the 
electrostatic coating with polycationic polymers such as chitosan (261, 262, 263). Typically, 
the establishment of cationic microparticles surfaces may be performed by incubation of 
previously prepared particles in an aqueous solution of the cationic agent. Direct coating of 
nascent particles in the course of a typical solvent evaporation/extraction process is achieved 
by addition of cationic surfactants or polymers to the aqueous extraction phase (264, 265). A 
third approach to obtain PLGA particles with cationic surface charge is the coencapsulation of 
a cationic lipid or a polyelectrolyte through spray drying (266). The purpose of PLGA 
microparticles bearing a cationic surface charge may be to provide a positively charged 
binding site for the adsorption, condensation and stabilization of nucleic acid 
biopharmaceuticals (plasmid DNA, mRNA), or antisense oligonucleotides, through 
electrostatic interaction (267, 268), or to render the particles mucoadhesive, e.g. in view of 
nasal and pulmonary delivery (269).  
Chitosan is highly bioadhesive and has been reported to enhance the permeability of the nasal 
mucosa (270, 271, 272). Thus, besides offering a substrate for the adsorptive deposition or 
conjugation of bioactive ligands, chitosan microparticles feature intrinsic bioadhesive and 
permeation enhancing properties, which make them particularly suitable for nasal and 
pulmonary administration.  
Results obtained with PLGA microspheres led us to develop a novel actively mucoadhesive 
PLGA microspheres system to improve pulmonary delivery of RFP by coating the particle 
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surface with the mucoadhesive polymer chitosan. RFP-encapsulated PLGA microspheres 
coated with chitosan were prepared by the emulsion solvent diffusion method in water (WSD 
Method).  
The influence of chitosan concentration on microparticle size distribution, entrapment 
efficiency (E%), nebulization efficiency (NE%) and leakage upon nebulization was studied. 
The toxicity of chitosan microspheres were evaluated by using A549 alveolar epithelial cells. 
7.1. Materials and Methods 
7.1.1. Material 
Medium molecular weight chitosan with a deacetilation grade of about 87% was, PLGA 
(75:25, mol. Wt 85,2 kDa), rifampicin (RFP), acetic acid, poly-vinyl alcool (PVA)  were 
provide by Sigma Aldrich Chemie (Germany).  Lyophilised bovine submaxillary glands  
mucin (type I-S) was purchase from Sigma Aldrich. 
The A549 epithelial alveolar cell line (passage 31) was a kind gift from Dr. Ben Forbes 
(School of Pharmacy, Kings College, London) and these cells were cultured in Ham’s F12-K 
medium (Sigma Aldrich), supplemented with 10% fetal bovine serum (Gibco BRL Life 
Technology, Grand Island, NY, USA), 100 µg/ml penicillin G (Sigma Aldrich), and 100 
µg/ml streptomycin sulphate (Sigma Aldrich ) at 37°C in a humidified 95% air/5% CO2 
environment. Cultures (monolayers in tissue culture flasks, 75 cm2) were fed with fresh 
medium every 48 h. 
All other reagents were of the highest grade commercially available. Water was always used 
in demineralised form. 
7.1.2. Preparation of RFP-Loaded PLGA Coated Chitosan Microspheres 
Also in this case WSD Method was used. Chitosan was dissolved in 50 ml of acetic acid 
buffer solution at pH 4.4, PVA (1%) was also dissolved in this buffer. The PLGA (100 mg) 
and RFP (2mg/ml) were dissolved in 5 ml of DCM which was poured into 50 ml of aqueous 
coating polymer solution prepared beforehand at 2 ml/min under stirring at 600 rpm using 
Ultraturrax® at room temperature. The PVA dissolved in the aqueous solution of coating 
polymer prevented aggregation of the emulsion droplets and sticking of the polymers to the 
propeller shaft during agitation. The entire dispersed system was then centrifuged (4500 rpm 
15 min) and the sediment was resuspended in distilled water. This process was repeated and 
the resultant dispersion was then subjected to freeze-drying overnight.  
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7.1.3. Characterization of RFP-Loaded PLGA Coated Chitosan Microspheres 
7.1.3.1. Particle Sizing and Morphology 
The microspheres were analysed for their size and polydispersity index on Zetasizer Nano ZS, 
Malvern instruments, based on Photon Correlation Spectroscopy, at a scattering angle of 90° 
and temperature of 25°. 
Measurements were carried out both for fresh and freeze-dried samples. Before counting, the 
samples were diluted with a 0.05% (w/v) tween 80 water solution in order to prevent 
precipitation during the measurements. Results are the means of triplicate experiments. 
7.1.3.2. Surface Charge (Zeta-Potential) 
The surface charge of the microspheres was determined with Zetasizer Nano ZS, Malvern 
instruments. The measurements were carried out in an aqueous solution of KCl 0,1N. 
Immediately before the determinations microspheres were diluted with KCl solution. The 
measured values were corrected to a standard reference at temperature of 20°. Results are the 
means of triplicate experiments. 
7.1.3.3. Particle Morphology 
In preparation for scanning electron microscopy (SEM) several drops of the microsphere 
suspension were placed on an aluminum stub having previously been coated with adhesive. 
The samples were evaporated at ambient temperature until completely dried, leaving only a 
thin layer of particles on the stub. All samples were sputter coated with gold-palladium 
(Polaron 5200,VG Microtech,West Sussex, UK) for 90 seconds (2.2 kV; 20 mA; 150–200A°) 
under an argon atmosphere. The SEM (Model 6300, JEOL, Peabody, NY) was operated using 
an acceleration voltage of 10 kV. 
7.1.3.4. Measurement of Loading Efficiency of RFP in PLGA Coated Chitosan 
Microspheres 
The rifampin content of each lot of microspheres was determined by first extracting the 
rifampin and quantifying the amount of drug spectrophotometrically. A series of rifampin 
solutions of known concentrations in acetonitril were prepared, and absorbances were 
measured in order to generate a standard curve. 
The drug encapsulation efficiency was calculated as the percentage of drug entrapped in 
microspheres compared with the initial amount of drug recovered in unpurified samples. The 
concentration of rifampin contained in each sample was determined by measuring the 
absorbance on a spectrophotometer at 485 nm. 
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7.1.3.5. Nebulization of Microspheres 
A compressor nebuliser system (Medel Aerofamily, Italy) was used in the study. A volume of 
3 ml of sample was used for the nebulization. The aerosols containing RFP-loaded PLGA 
coated chitosan microspheres were collected in water using a modified 3 stages glass 
impinger. The impinger device was utilized with the collecting flask containing 3 ml of water 
to which the aerosol was introduced through a calibrated glass tube and critical orifice 
delivering the jet of aerosol 5mm above the bottom of the flask. 
After aerosolization (10 min.), the impinger contents  were assayed in order to evaluate the 
effect of nebulization on drug leakage of microspheres. It was also important to determine the 
total amount of formulation nebulised into the apparatus. The nebulization efficiency (N.E%) 
of microsphere formulations is defined as the total output of drug collected on the impinger as 
a percentage of  the total  submitted to nebulization.  
 
NE% = (Aerosolised drug /Total drug placed in nebuliser) x 100 
 
Because nebulization can lead to drug leakage, it is important also to determine the 
nebulization efficiency of the encapsulated drug (NEED%). This parameter is defined as the 
percentage of aerosolised drug that remains encapsulated after nebulization. A portion of 
nebulised sample was purified by centrifugation and the amount of drug in the sample after 
and before centrifugation was assayed. 
After nebulization particle size distribution was measured in order to ervaluate the effect of 
this process on this parameter. 
7.1.4. Release Studies/Stability Studies 
In vitro release of RFP from PLGA coated chitosan microspheres was determined using as the 
release mediums, phosphate buffer pH 7.4 and acetate buffer pH 4.4, in order to simulate the 
condition in lungs and in particular the conditions inside lysosomes and phagosomes. Freeze-
dried formulations were suspended in 500 ml of the dissolution medium, and the amount of 
microspheres was varied in order to kept constant the amount of drug (25 mg). The 
experiments were carried out at 37 ± 0.3°C at a rotation speed of 100 ± 2 rpm. A measure of 1 
ml samples was withdrawn at appropriate time intervals and centrifuged at 10000 rpm. 
Supernatants were diluted suitably with acetonitrile and absorbance of the resulting solution 
was measured at 485 nm. The residue (after centrifugation) was redispersed in 1 ml of the 
fresh dissolution medium and replaced back into the dissolution apparatus. The cumulative 
amount of RFP was obtained from the calibration curves of RFP in acetonitrile. The stock 
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standard solution of RFP (2 mg/ml) was prepared by dissolving the drug in acetonitrile and 
storing at 4°C. A standard calibration curve was built up by using standard solutions prepared 
by dilution of the stock standard solution with acetonitrile. 
7.1.5. Mucoadhesive Studies 
7.1.5.1. Adsorption of Mucin on Chitosan Microspheres 
Bradford colorimetric method was used to determine the free mucin concentration in order to 
assess the amount of mucin adsorbed on the microspheres and its effect on the assessment of 
mucoadhesive behavior of  PLGA coated chitosan microspheres. 
Standard calibration curves were prepared from 2 mL of mucin standard solutions (0.25, 0.5, 
0.75, and 1 mg/2 mL). After adding Bradford reagent, the samples were incubated at 37°C for 
20 minutes and then, the absorbance of the solution was recorded at 595 nm in a UV 
spectrophotometer. Triplicate samples were run. All the samples were determined with the 
same procedure. The mucin content was calculated from the standard calibration curve.  
Mucin aqueous solution with different concentrations (0.025, 0.1, and 0.5 mg/mL) were 
prepared. Freeze-dried chitosan coated PLGA microspheres (20 mg) were dispersed in the 
above mucin solutions, vortexed, and shaken at room temperature. Then, the dispersions were 
centrifuged at 5000 rpm for 10 minutes, and the supernatant was used for the measurement of 
the free mucin content. 
7.1.6. Cell Culture 
The human A549 alveolar epithelial cell line (passage 31) shows similar features as type II 
alveolar epithelial cells. The cells were grown as monolayers in 35 mm tissue culture dishes 
incubated in 100% humidity and 5% CO2 at 37°C. HAM’S medium medium containing 365 
mg/L L-glutamine, supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL 
penicillin, and 100 µg/mL streptomycin  was used as the growth media. The cells that form 
the monolayers were harvested with trypsin (0.25%) centrifuged at low speed (1600 g, 4 min), 
resuspended in fresh medium and plated at a concentration of 2 x 105 cells/dish. The cells 
were grown to confluence on tissue culture dishes for 3 to 4 days.  
7.1.6.1. MTT Assay 
For dose-dependent studies, cells were treated with both RFP-loaded PLGA coated CTS  
microspheres at different concentration in RFP. The effect of RFP in microspheres on the 
viability of cells was determined by [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] MTT assay (256). The dye is reduced in mitochondria by succinic dehydrogenase to 
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an insoluble violet formazan product. A549 cells (105 cells/well) were cultured on 24-well 
plates with 500 µl of medium for 24 hours, with and without the tested compounds. Then 50 
µl of MTT (5 mg/ml in PBS) were added to each well and after 2 h, formazan crystals were 
dissolved in DMSO. Absorbance at 580 nm was measured with a spectrophotometer. On the 
basis of this assay IC50 values were obtained in three independent experiments for each 
formulation. In all assays three different concentrations were used. In order to evaluate 
changes in viability caused by the tested compounds, living cells as well as those in early and 
late stages of apoptosis and necrosis were counted. All other methods were also carried out 
after 24 h incubation. The data in this study were expressed as mean ± S.D. 
7.1.7. Statistical Analyses 
All experiments were repeated at least three times. Results are expressed as means ± standard 
deviation. A difference between means was considered significant if the p value was less than 
or equal to 0.05. 
7.2. Result And Discussion 
7.2.1. Preparation of RFP-Loaded Chitosan Microspheres 
Microparticulate drug delivery systems are of considerable therapeutic interest. Currently, this 
field is dominated by the use of poly(lactide-co-glycolide) (PLGA) type microspheres. 
However, because of the deficiency of suitable functional groups on their surface, 
conventional PLGA microspheres lack the possibility of surface modifications for specialized 
targeting or other purposes. Such modifications are thought to improve greatly the 
effectiveness of microparticulate delivery systems. 
To solve this problem, a WSD process to coat conventional PLGA particles by means of a 
biocompatible polymer, chitosan, was used. 
Whit this method a direct coating of nascent particles was achieved in the course of a typical 
solvent evaporation/extraction process by addition of the polymer to the aqueous extraction 
phase. 
Four chitosan concentrations (0.1%, 0.25%, 0.5% and 0.75%) were chosen in order to 
evaluate the relationship between the polymer concentration (and the solution viscosity) and 
different parameters like encapsulation efficiency, stability of microparticles during 
nebulization process and drug leakage after nebulization.  
Composition of chitosan coated RFP-loaded PLGA microspheres is reported in table 7.1. 
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Table 7.1 : Rfp-Loaded Plga Coated Chitosan Microspheres: Composition  
 
 
 
 
 
 
 
 
7.2.2. Size and Morphological Characteristics Of Microspheres 
Mean diameter of the surface-modified PLGA microparticles with different amount of 
chitosan, prepared by the WSD method, are shown in Table 7.2. Average diameter of coated 
microspheres ranged from 2.9 to 1.5 µm, while uncoated PLGA particles had a mean size of 
2,9 µm. Freeze-dried microspheres, readily redispersed in aqueous medium under manual 
stirring, showed almost the same particle diameter as that before lyophilization, (data not 
shown). 
As can be seen from te table, coating of particles with chitosan led to an increase of 
microsphere size, which was particularly evident when the lowest amount of the hydrophilic 
polymer was used. However this is probably due to the stabilizant effect of PVA/chitosan 
combination and also to increasing interactions between the two polymers (chitosan and 
PLGA) as the amount of chitosan increased. Moreover, particle-size distribution did not 
change significantly from batch to batch. In fact, polydispersity index of all prepared batches 
was always quite big as a consequence of the high polydispersion of the obtained 
formulations. However, no aggregation could be observed as confirmed by SEM 
investigations. 
 
 
 
 
 
 
 
 RFP PLGA PVA Chitosan  
No Chit. 2mg/ml 2mg/ml 1% - 
0,1% Chit. 2mg/ml 2mg/ml 1% 0.1% 
0,25% Chit. 2mg/ml 2mg/ml 1% 0.25% 
0,5% Chit. 2mg/ml 2mg/ml 1% 0.5% 
0,75% Chit. 2mg/ml 2mg/ml 1% 0.75% 
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Table 7.2: Particle Size and Zeta Potential of RFP-Loaded PLGA Coated Chitosan 
Microspheres 
Formulation Particle Size (nm ± SD) P.I ± SD 
Zeta Potential 
(mV ± SD) 
Withouth RFP 
Zeta Potential 
(mV ± SD) 
With RFP 
No Chit. 2535 ± 58,01 0.506 ± 0,055 +4.70 ± 0.10 -4.80 ± 0.10 
0,1% Chit. 2900 ± 59.54  0.571 ± 0.018 +6.90 ± 0.10 +14.9 ± 0.10 
0,25% Chit. 2807 ± 85.89 0.459 ± 0.053 +8.40 ± 0.20 +19.10 ± 0.40 
0,5% Chit. 2567 ± 19.76 0.494 ± 0.059 +9.40 ± 0.10 +31.10 ± 0.40 
0,75% Chit. 1407 ± 51.23 0.392 ± 0.020 +19.50 ± 0.40 +37.00 ± 0.40 
 
As can be seen, a different morphology can be observed from the uncoated and coated 
particles. In fact SEM micrograph 2a shows that uncoated PLGA microspheres have regular 
and uniform spherical shape with a smoooth surface. However coating PLGA microparticles 
with chitosan led to a modification of microspheres surface, which became rough. Figure 7.1. 
 
   
 a b 
   
 c d 
Figure 7.1: Sem Micrographs of RFP-Loaded PLGA Coated Chitosan Microsferes: 
0,1% chitosan (a and b), 0,75% chitosan (c and d) 
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7.2.3. Surface Charge 
Zeta potential of microparticles differed significantly between uncoated PLGA and chitosan-
coated PLGA microspheres (Table 7.2). Chitosan coating shifted the negative zeta potential of 
pure PLGA microspheres to positive values, in relation to the used chitosan concentration. 
Increasing chitosan concentrations shifted the zeta potential from negative to highly positive 
values, as a consequence of the increasing amount of free ionizable amino groups. But zeta 
potential is also affected by the presence of RFP. In fact RFP encapsulated microparticles 
showed an increased zeta potential value. For instance, encapsulation of RFP shifted the zeta 
potential of uncoated PLGA particles from 2.80mV to -4.80 mV, whereas for chitosan-coated 
particles the zeta potential values changed from 4mV to 14mV, and from 19mV to 37mV for 
the lowest chitosan concentration and the highest chitosan concentration respectively (Table 
7.2). It means that the zeta potential of the PLGA particles was affected by chitosan 
concentration in the external phase.  
7.2.4. Entrapment Efficiency (E%) 
Figure 3 shows encapsulation efficiency (E%) of prepared microspheres. In the present part of 
the work the influence of chitosan coating concentration on the RFP entrapment in PLGA 
coated chitosan microspheres was evaluated. The presence of chitosan coating on 
microspheres enhanced E%, which increased as chitosan concentration increased. 
In fact the highest E% were found for formulations with the highest amount of chitosan (0.5% 
and 0.75%). It has been reported that added hydrophilic polymers to primary emulsion as a 
stabilizer could prevent loss of drug from the external phase.  
The presence of chitosan on particle surface is probably capable of preventing drug leakages 
during preparation but in particular during purification process (273).  
Figure 7.2 also shows that freeze-drying of microparticles did not result in statistically 
relevant RFP leakage from any of the prepared microspheres. 
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Figure 7.2: Entrapment Efficiency (E%) of Rfp-Loaded Plga Coated Chitosan 
Microsferes 
 
7.2.5. Nebulization Studies of Chitosan Microspheres 
Nebulization studies carried out to evaluate stability and suitability of chitosan coated PLGA 
particles for pulmonary/nasal administration. 
Nebulization led to a reduction of mean particle diameter, but not a reduction of P.I.  
These results demonstrate that the prepared microspheres had a multimodal distribution and 
that nebulization led to a separation of the particles in all the three stages of the used 
impinger. 
 
Table 7.3: Particle Size of RFP-Loaded PLGA Coated Chitosan Microspheres Before 
and After Nebulization 
 
Formulation 
Particle Size (nm 
± SD) 
Before nebulization 
P.I ± SD 
Particle Size 
(nm ± SD) 
After nebulization 
P.I ± SD 
No Chit. 2535 ± 58,01 0.506 ± 0,055 1463 ± 50,33 0,637 ± 0,018 
0,1% Chit. 2900 ± 59.54  0.571 ± 0.018 1746 ± 25,16  0,558 ± 0,039 
0,25% Chit. 2807 ± 85.89 0.459 ± 0.053 1786 ± 38,15 0,523 ± 0,084 
0,5% Chit. 2567 ± 19.76 0.494 ± 0.059 1700 ± 32,28 0,754 ± 0,092 
0,75% Chit. 1407 ± 51.23 0.392 ± 0.020 1266 ± 32,14 0,756 ± 0,098 
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For all microsphere formulations nebulization efficiency and drug leakage after nebulization 
were evaluated. Both of these parameters depend on the stability of particles.  
As can be seen in figure 7.3 all coated formulations showed a good nebulization efficiency 
that increased as chitosan concentration increaed. This is probably because chitosan on the 
surface can reduce the drug leakage during the nebulization process.  
Similarly to chitosan particles described previously (chapter 4 and 5), chitosan coated PLGA 
microsphere dispersions showed a viscosity that increased as the chitosan concentration 
increased. However, in this case particles showed good aerodinamic propertiesas they could 
be easily nebulized (figure 7.4). 
A similar trend was observed when NEED% was calculated. As shown in figure 7.5, the 
amount of RFP still encapsulated after the nebulization was improved by coating the PLGA 
particles with the hydrophilic polymer.once again, results demonstrated that nebulization 
properties of the prepared microspheres improved as chitosan concentration increased. In 
particular formulation 0,75% was able to retain 63,51% of the entrapped drug 
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Figure 7.3: Nebulization Efficiency (NE%) of RFP-Loaded Plga Coated Chitosan 
Microsferes 
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Figure 7.4: Nebulization Efficiency of the Encapsulated Drug (NEED%) of Rfp-Loaded 
Plga Coated Chitosan Microsferes 
 
Freeze-dried microspheres were re-suspended in water and also in this case all the parameters 
were evaluated. As can be seen in figures 7.3 and 7.4 NE% and NEED% remained almost the 
same after freeze-drying and these results suggested that the stability of PLGA coated 
chitosan microspheres was not affected after liophilization and redispersion process. 
7.2.6. Release/Stability Studies 
Release studies were carried out by using two different release medium, phosphate buffer at 
pH 7.4 and acetic acid buffer at pH 4.4, in order to have the same pH values present inside 
phagosomes and lysosomes and to evaluate the effect of pH on RFP release from chitosan 
microspheres. In Figures 7.5 and 7.6, RFP release profiles from chitosan coated RFP-loaded 
PLGA microspheres at pH 7.4 and 4.4 buffer solutions respectively, are shown. At both pH 
values, about 25% of the drug is immediately released (2 hour) from the uncoated 
microspheres. This finding indicates that some of the drug is localized on the surface of the 
microspheres due to the partition of the drug into the surface-active agent layer adsorbed at 
the surface of the emulsion droplets. After this initial burst, drug release is almost constant, 
and after 72h 55% of the drug is released from the microspheres. For uncoated PLGA 
particles the fastest release was observed at pH 7.4 although no difference in the initial burst 
could be noticed. However, as can be seen drug release from uncoated particles was not 
affected by the medium pH. On the contrary, coating the microspheres with chitosan altered 
the drug release pattern: the initial burst was reduced and the reduction increased as chitosan 
amount increased, from 24 to 7% for uncoated and coated particles respectively.  
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 Figure 7.5: Release Studies pH 7.4 Figure 7.6: Release Studies pH 4.4 
 
This behaviour is more evident at pH 7.4. In fact, at pH 4.4 release from the coated particles is 
faster even if there is, also in this case, a reduction of the initial burst. Therefore, results 
confirm the capacity of chitosan on the particle surface to prevent drug leakage in the initial 
phase of the release. The increased release at pH 4.4 can be explained as a consequence of the 
ionization of D-glucosamine residues that resulted in extensive swelling and faster drug 
release. 
However, as can be seen in figures 7.5 and 7.6, pH of the release medium does not affect drug 
release  
7.2.7. Mucoadhesive Studies 
It has been reported that chitosan has preferable properties for improving drug absorption, 
such as protection of the drug against enzymatic degradation (274), by opening the 
intercellular tight junction of the lung epithelium and absorption-enhancing effects in the 
nasal/pulmonary mucosa (275, 276, 277). However, whether or not chitosan enhances drug 
absorption in the lungs remains to be determined. For this reason the mucoadhesive properties 
of  RFP-loaded PLGA coated chitosan microspheres were evaluated by measuring the 
adsorption/association of mucin with the microspheres.  
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As can be seen from figure 7.7, the chitosan coating of PLGA particles improuves greatly the 
mucoadhesive properties of the RFP-loaded microspheres. The results confirm those obtained 
with chitosan microspheres and PLGA particles described above (chapters 4 and 6). 
Moreover, they are also a logical consequence of the zeta potental values measured (table 
7.2). indeed, it is well known that the main mechanism of mucoadhesion is interaction 
between opposite charged molecules.  
Therefore, the positive charge of the chitosan coated microspheres increased the 
mucoadhesive properties of the negatively charged uncoated PLGA microspheres.  
As can be seen from the graph, for chitosan coated particles the percentage of mucin adsorbed 
increased as the mucin concentration increased from 0.025 to 0.1 mg/ml reaching a 100% 
mucoadhesion. 
0
20
40
60
80
100
No chit. 0,1% Chit 0,25% Chit 0,5 % Chit 0,75% Chit
%
 
o
f m
u
ci
n
 
ad
so
rb
ed
 
Figure 7.7: Mucoadhesive Behaviour of Rfp-Loaded Plga Coated Chitosan Microsferes 
 
7.2.8. Viability Studies with A549 Cells 
The cytotoxic effects of RFP against A549 cells were examined by MTT assay. In the 
experiments, the cytotoxicity was evaluated by varying the concentration of RFP and RFP 
entrapped in PLGA coated chitosan microspheres. Cytotoxicity was observed to be 
concentration-dependent for free RFP and for all the formulations. The highest cytotoxic 
effects were found for free RFP. In fact, as can be seen in figure 7.8, also with the lowest 
concentration of RFP the viability is very low and it means that the free drug can cause side 
effects also when it is nebulized directly into the lung, where the infection is. RFP 
incorporated in PLGA coated chitosan microspheres were less toxic, but toxicity was still a 
function of RFP concentration. In fact, empty microspheres were always less toxic than RFP-
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coating particles. The highest cellular viability was found for particles more concentrated in 
chitosan while the lowest for the uncoated PLGA particles. Therefore chitosan reduced 
toxicity effects of plain PLGA as a consequence of its deposition on the surface of PLGA 
microspheres.  
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Figure 7.8: Viability Studies of RFP-Loaded PLGA Coated Chitosan Microsferes with 
A549 Cells 
7.3. Conclusion 
PLGA microspheres coated with mucoadhesive polymer were successfully prepared by the 
emulsion solvent diffusion methods in water (WSD). The surface coating of microspheres 
with chitosan, was confirmed by the change in zeta potential. The excellent mucoadhesion 
properties of chitosan-coated PLGA microspheres were proved by their significant adsorption 
to the mucin solution mainly due to the electrostatic attraction between the amino groups of 
chitosan and the negatively charged mucin. The chitosan-coated PLGA microspheres, which 
improved the RFP loading, were applied to improve the pulmonary delivery of the drug by 
nebulization. The particle diameter of the aqueous dispersion of the microspheres was an 
important factor to enclose the particles in the aerosolized aqueous droplets produced with the 
nebulizer.  
The elimination rate of chitosan-modified microspheres from the lungs can decrease 
significantly due to the mucoadhesive property after pulmonary administration compared to 
that of the unmodified microspheres. Furthermore, it was supposed that chitosan on the 
surface of the microspheres enhances the drug absorption by opening the intercellular tight 
junctions in the lung epithelium. These findings demonstrated that the chitosan-modified 
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PLGA microspheres is useful for improving drug delivery via a pulmonary route due to 
prolonged mucoadhesion for sustained drug release at the absorption site and the absorption-
enhancing action of the surface modifier, chitosan. 
Viability studies showed that the presence of chitosan on the surface of particles was able to 
reduce the toxicity of uncoated PLGA particles and also that the increase of chitosan did not 
affect the viability of A549 cells. However the viability was for both plain RFP and RFP 
loaded particles, concentration dependent.
  
 
 
 
118 
  
 
 
 
119 
8. Final Discussion and Conclusions 
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In this thesis we described the preparation of RIF-loaded microparticles, designed for use as 
freeze-dried formulations for rapid re-hydration-nebulization and RFP delivery to lung 
macrophages. During this study we evaluated particles made with synthetic or natural 
polymers, (PLGA and chitosan) as well as mixtures of the two polymers (PLGA/chitosan), 
under identical conditions in order to compare the different cases. Particles were evaluated in 
terms of RFP loading and stability during freeze-drying and nebulization.  
Comparison of the results obtained from the three different particle types, let us to conclude 
that RFP loading is generally higher in the order PLGA/chitosan > PLGA>chitosan (although 
this does not apply for all the different samples evaluated in each group). Within the chitosan-
group, RFP E% is affected by the chitosan concentration used during chitosan particle 
formation, but in all cases RFP-loading is considerably lower in chitosan microspheres 
compared to PLGA. For the PLGA microparticles it seems that RFP loading is higher when 
RFP is initially added in the system through the organic phase (during microsphere 
preparation) a fact that is in line with the lipophilic nature of this drug.  
Considering the important characteristics of nebulization ability (NE%) and stability 
(NEED%), the order for particles is again (as for E%) PLGA/chitosan > PLGA > chitosan, 
while significant differences between the different particle compositions within the groups 
were observed. For chitosan microparticles NE% increases significantly with decreasing 
chitosan concentration, due to the easier nebulization of dispersion with lower viscosity 
(Bridges et al, 2000). The microspheres that exhibited the highest stability during nebulization 
(PLGA 1 and 2, and PLGA/chitosan 0,75%), were those with a higher compact and stable 
structure (compared to chitosan particles), as proven by their morphological assessment. The 
PLGA-based particles showing the highest stability during nebulization were also found to 
have constant mean diameter before and after the process.  
The high stability demonstrated for PLGA-based particles, during nebulization, may be 
related to the possibility of reaction between the amino groups of RFP and the terminal 
carboxyl groups of PLGA (278). This also explains the higher E% found for these 
microparticles than those of chitosan particles. Nevertheless, the fact that chitosan-coated 
PLGA particles are even better in terms of RFP E%, NE% and NEED% compared to 
uncoated PLGA particles suggests that chitosan acts as a stabilizer for the particles, possibly 
by interacting with PLGA (the amino groups of chitosan with the terminal carboxyl groups of 
PLGA). This explains the almost linear dependence of particle stability on their chitosan 
content. 
8. Final Discussion and Conclusions 
 
 
 
 
121 
Recently, it was proposed that for improved product shelf-life, particles intended for alveolar 
delivery of drugs could be prepared as freeze dried formulations that will be re-hydrated only 
prior to nebulization (279). All particles prepared herein were found to be very stable after 
freeze-drying and the freeze-drying/re-hydration cycle did not affect their NE% and NEED%. 
Additionally, the quality of the powder produced was always good since it could be easily re-
hydrated). 
Summarizing the results of this study, we may conclude that the PLGA polymer is better that 
chitosan, for the formation of particles that could deliver RFP to alveolar macrophages by 
nebulization. However, the combination of the two polymers at proper quantities results in the 
formation of very stable microspheres with high loading capacity for RFP. 
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